<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005473.pub2" GROUP_ID="DEPRESSN" ID="964002112720342554" MERGED_FROM="" MODIFIED="2008-11-03 19:51:06 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;Old title: Pharmacotherapy Augmentation Strategies in Treatment-Resistant Anxiety Disorders&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 18:49:08 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-03 19:51:06 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</TITLE>
<CONTACT MODIFIED="2008-11-03 19:51:06 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="18674" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Ipser</LAST_NAME><EMAIL_1>jonathan.ipser@uct.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>MRC Research Unit for Anxiety and Stress Disorders</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>PO Box 19063</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><FAX_1>+ 27 21 933 5790</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-03 19:51:06 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="18674" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Ipser</LAST_NAME><EMAIL_1>jonathan.ipser@uct.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>MRC Research Unit for Anxiety and Stress Disorders</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>PO Box 19063</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><FAX_1>+ 27 21 933 5790</FAX_1></ADDRESS></PERSON><PERSON ID="D28E115A82E26AA201E74FE923832C35" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paul</FIRST_NAME><LAST_NAME>Carey</LAST_NAME><EMAIL_1>pcarey@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>PO Box 19063</ADDRESS_1><ADDRESS_2>Tygerberg</ADDRESS_2><CITY>Tygerberg</CITY><ZIP>7550</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY></ADDRESS></PERSON><PERSON ID="18675" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yumna</FIRST_NAME><LAST_NAME>Dhansay</LAST_NAME><POSITION>Registrar</POSITION><EMAIL_1>yumnadhansay@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>MRC Research Unit for Anxiety and Stress Disorders</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>P.O. Box 19063</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9335790</PHONE_1></ADDRESS></PERSON><PERSON ID="D458884982E26AA201CF22BB89216010" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nuraan</FIRST_NAME><LAST_NAME>Fakier</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>nuraan@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>P.O. Box 19063 </ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON><PERSON ID="18673" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Soraya</FIRST_NAME><LAST_NAME>Seedat</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>s.seedat@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>MRC Research Unit for Anxiety and Stress Disorders</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>PO Box 19063</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389374</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON><PERSON ID="6972" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Stein</LAST_NAME><POSITION>Professor &amp; Chair</POSITION><EMAIL_1>dan.stein@uct.ac.za</EMAIL_1><EMAIL_2>djs2@sun.ac.za</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Anzio Road</ADDRESS_1><ADDRESS_2>Rondebosch</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7700</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389161</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-03 18:48:07 +0000" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;New studies found and included or excluded: 03/08/05&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 18:48:07 +0000" NOTES_MODIFIED_BY="Rachel Churchill">
<UP_TO_DATE>
<DATE DAY="22" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="8" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>MRC Unit on Anxiety Disorders</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Cape Town, Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>MRC Research Unit on Anxiety and Stress Disorders</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-03 18:46:05 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-03 18:46:05 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-03 18:46:05 +0000" MODIFIED_BY="[Empty name]">Medication augmentation for treatment-resistant anxiety disorders</TITLE>
<SUMMARY_BODY>
<P>Anxiety disorders are highly prevalent and result in substantial socio-economic and personal costs. A significant<B> </B>proportion of patients with anxiety disorders fail to respond to first-line medication interventions. This was a systematic review of 28 short-term randomised controlled trials of medication augmentation for the treatment of such individuals (740 participants). A significantly larger proportion of patients responded to medication (31.8%) than to placebo (13.6%), (nine trials, 250 participants). Symptom severity was also significantly reduced (14 trials, 337 participants). A substantial proportion of the efficacy evidence base was for the augmentation with antipsychotics of serotonin reuptake inhibitors for obsessive compulsive disorder. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>A large proportion of patients with anxiety disorders fail to respond to first-line medication interventions, despite evidence of the effectiveness of these agents. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of medication versus placebo augmentation in the treatment of patients with anxiety disorders who have failed to respond adequately to first-line drug therapies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Depression, Anxiety &amp; Neurosis Group (CCDAN) specialised registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 3/8/2005, , MEDLINE (January 1966 to July 2005) and PsycINFO (1966 to 2005, Part A). Unpublished trials were identified through the Controlled Trials database and the National Institute of Health's Computer Retrieval of Information on Scientific Projects (CRISP) service (1972 to 2005). Additional studies in any language were sought in reference lists of retrieved articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials (RCTs) of the medication augmentation of pharmacotherapy for treatment resistant anxiety disorders.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two raters independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. Investigators were contacted to obtain missing data. Summary statistics were stratified by class of augmentation agent and anxiety disorder. Overall effect estimates were calculated using<B> </B>a random-effects model, heterogeneity was assessed and subgroup/sensitivity analyses were undertaken. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Twenty eight short-term (average of seven weeks) randomised controlled trials (740 participants) were included in the review, 20 of which investigated augmentation of medication for treatment-resistant obsessive compulsive disorder (OCD). Summary statistics for responder status from nine trials demonstrate overall superiority of a variety of medication agents to placebo (relative risk of non-response (RR) 3.16, 95% CI 1.08 to 9.23). Similarly, symptom severity was significantly reduced in the medication groups, relative to placebo (number of trials (N) = 14<B>,</B> standardised mean difference (SMD) -0.87, 95% CI -1.37 to -0.36). There is no evidence of a difference between medication and placebo in total dropout rate, or in the number of dropouts due to adverse events. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Medication augmentation can be an effective and well-tolerated short-term treatment strategy for non-responders to first-line pharmacotherapy of anxiety disorders. However, any conclusions must be tentative in view of methodological and clinical heterogeneity, and the fact that much of the relevant database is based on antipsychotic augmentation trials in OCD patients resistant to serotonin reuptake inhibitors (SRIs). Additional data are needed to address several areas, including the efficacy of augmentation over the longer-term, and the value of medication augmentation in comparison to other strategies (eg switching medication, adding psychotherapy). </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Anxiety disorders (including generalised anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder and social anxiety disorder) are amongst the most prevalent of the psychiatric disorders, with lifetime prevalence estimates higher than for<B> </B>mood disorders (<LINK REF="REF-Karno-1988" TYPE="REFERENCE">Karno 1988</LINK>; <LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK>; <LINK REF="REF-Kessler-2005" TYPE="REFERENCE">Kessler 2005</LINK>). Anxiety disorders are also associated with significant comorbidity (<LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK>; <LINK REF="REF-Kessler-2005" TYPE="REFERENCE">Kessler 2005</LINK>), disability, impaired quality of life (<LINK REF="REF-Mendlowicz--2000" TYPE="REFERENCE">Mendlowicz 2000</LINK>) and contribute significantly to the global burden of disease (<LINK REF="REF-Murray-1994" TYPE="REFERENCE">Murray 1994</LINK>). The financial cost of anxiety disorders in the early 1990s was estimated at 42.3 billion U.S dollars in the United States (<LINK REF="REF-Greenberg-1999" TYPE="REFERENCE">Greenberg 1999</LINK>).</P>
<P>A number of specific pharmacologic agents have proven effective as first-line treatments for anxiety disorders. Meta-analyses have demonstrated that antidepressant agents are effective in OCD (<LINK REF="REF-Ackerman-2002" TYPE="REFERENCE">Ackerman 2002</LINK>; <LINK REF="REF-Stein-1995" TYPE="REFERENCE">Stein 1995</LINK>; <LINK REF="REF-Eddy-2004" TYPE="REFERENCE">Eddy 2004</LINK>), generalised anxiety disorder (GAD) (<LINK REF="REF-Mitte-2005" TYPE="REFERENCE">Mitte 2005</LINK>), panic disorder (PD) (<LINK REF="REF-Bakker-2002" TYPE="REFERENCE">Bakker 2002</LINK>; <LINK REF="REF-Boyer-1995" TYPE="REFERENCE">Boyer 1995</LINK>; <LINK REF="REF-Mitte-2005b" TYPE="REFERENCE">Mitte 2005b</LINK>), post-traumatic stress disorder (PTSD) (<LINK REF="REF-Stein-2006" TYPE="REFERENCE">Stein 2006</LINK>) and social anxiety disorder (SAD) (<LINK REF="REF-Blanco-2003" TYPE="REFERENCE">Blanco 2003</LINK>; <LINK REF="REF-Fedoroff-2001" TYPE="REFERENCE">Fedoroff 2001</LINK>). Expert consensus guidelines suggest the use of selective serotonin reuptake inhibitors (SSRIs) and/or noradrenergic and serotonin selective reuptake inhibitors (SNRIs) as first-line pharmacotherapeutic agents in these conditions (<LINK REF="REF-Bandelow-2002" TYPE="REFERENCE">Bandelow 2002</LINK>). Benzodiazepines, anticonvulsants and other agents are less well studied, but also show efficacy in some anxiety disorders.</P>
<P>Psychotherapy may also be effective for anxiety disorders, with the bulk of controlled trials focusing<B> </B>on cognitive-behavioural interventions. Randomised controlled trials<B> </B>of cognitive-behavioural psychotherapy (CBT) have shown that it is able to reduce the severity of symptoms across a range of anxiety disorders<B> </B>(<LINK REF="REF-Butler-2005" TYPE="REFERENCE">Butler 2005</LINK>). There is also a growing literature in which pharmacotherapy and psychotherapy have been compared in the treatment of anxiety disorders (<LINK REF="REF-Heimberg-1998" TYPE="REFERENCE">Heimberg 1998</LINK>; <LINK REF="REF-Fedoroff-2001" TYPE="REFERENCE">Fedoroff 2001</LINK>
<B>; </B>
<LINK REF="REF-Mitte-2005c" TYPE="REFERENCE">Mitte 2005c</LINK>). In research trials these are often equally effective interventions, although there is some evidence that pharmacotherapy has a more rapid onset (<LINK REF="REF-Heimberg-1998" TYPE="REFERENCE">Heimberg 1998</LINK>), while CBT has a more sustained effect (<LINK REF="REF-Power-1990" TYPE="REFERENCE">Power 1990</LINK>; <LINK REF="REF-Fedoroff-2001" TYPE="REFERENCE">Fedoroff 2001</LINK>).</P>
<P>Despite the availability of effective treatments for anxiety disorders, a significant number of patients with these conditions fail to respond optimally to first-line interventions. Treatment responses in anxiety disorders range from an estimated 40% to 60% in OCD (<LINK REF="REF-Pallanti-2002" TYPE="REFERENCE">Pallanti 2002</LINK>) to 60% to 80% in panic disorder (<LINK REF="REF-Bandelow-2004" TYPE="REFERENCE">Bandelow 2004</LINK>). For the purposes of this review, we will define patients who fail to respond to a first-line intervention as treatment-resistant, while those who show no change or whose symptoms worsen following several different interventions will be referred to as treatment-refractory (<LINK REF="REF-Pallanti-2002" TYPE="REFERENCE">Pallanti 2002</LINK>).</P>
<P>In clinical practice, several options are available for approaching the management of treatment-resistant anxiety disorders. These include increasing the dose and duration of pharmacotherapy, switching to a different medication, combining drugs with a similar mechanism of action, or augmenting a first medication with a second agent from the same or a different drug class. Augmentation of an agent with one from a different drug class is broadly supported by basic and clinical research suggesting the involvement of multiple neurotransmitters in anxiety disorders, and the possibility that these are rational targets for pharmacotherapy. The strategy of polypharmacy is not without concern, however, as it may increase the risk of side-effects.</P>
<P>A number of RCTs have recently addressed the effectiveness of medication augmentation in treating anxiety disorders (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>; <LINK REF="STD-Fineberg-2005" TYPE="STUDY">Fineberg 2005</LINK>; <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>; <LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>, <LINK REF="STD-Pollack-2006" TYPE="STUDY">Pollack 2006</LINK>; <LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>). This review aims to systematically evaluate pharmacotherapy augmentation trials in treatment-resistant and treatment-refractory anxiety disorders.</P>
</BACKGROUND>
<OBJECTIVES>
<P>(1) To use evidence from RCTs to provide an estimate of the overall efficacy of pharmacotherapy augmentation strategies in improving treatment response and reducing symptom severity for each treatment-resistant/refractory anxiety disorder. </P>
<P>(2) To determine whether particular augmentation strategies are more tolerable than others in the treatment of anxiety disorders. </P>
<P>(3) To identify which factors (clinical, methodological) predict response to augmentation strategies.</P>
<P>(4) To compare the effects of augmentation strategies on quality of life and on reduction of severity of comorbid disorders.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled trials of pharmacotherapy augmentation for anxiety disorders<B> </B>were considered for inclusion. The review included published and unpublished studies written in any language. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies of participants with treatment-resistant or refractory anxiety disorders were included. Treatment resistance was defined for the purposes of this review as lack of response on the primary outcome measures employed in the studies. A broad definition of treatment resistance was employed in anticipation of differences across trials in the operational definition of resistance.<B> </B>Trials that characterised their sample as treatment resistant, without providing evidence in terms of the lack of response on a validated outcome measure against which to assess this claim, were not included in the meta-analyses, but are instead described in a narrative fashion in the results section of the review. </P>
<P>No restriction on trial inclusion was applied in respect of subject age, inpatient/outpatient status, or secondary psychiatric comorbidity. Studies concerning anxiety symptoms that were part of the clinical presentation of another primary diagnosis (eg anxiety symptoms in depression) were, however, excluded. Current but not prior treatment with psychotherapy was used as an exclusion criterion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The review only included controlled pharmacotherapeutic augmentation trials in which ongoing medication was augmented with a separate agent. </P>
<P>Specific medication interventions were grouped according to medication class. These include: </P>
<UL>
<LI>antipsychotics (haloperidol, olanzapine, quetiapine, risperidone)</LI>
<LI>benzodiazepines (alprazolam, bromazepam, clonazepam)</LI>
<LI>selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)</LI>
<LI>trycyclic antidepressants (amitriptyline, clomipramine, desipramine, imipramine) </LI>
<LI>mono-amine oxidase inhibitors (brofaromine, moclobemide, phenelzine) </LI>
</UL>
<P>
<BR/>Medications which did not fall in these categories were classified as "Other medications" (buspirone, inositol, lithium, pindolol, prazosin, venlafaxine). </P>
<P>Control interventions included:<BR/> <BR/>
</P>
<UL>
<LI>placebo </LI>
<LI>other medication groups</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary and secondary outcome analyses were stratified by anxiety disorder and class of augmentation agent. </P>
<P>
<B>Primary outcomes</B>
<BR/>Both dichotomous outcome measures of treatment response and continuous symptom severity scales were included. Treatment response (number of responders) was determined from the improvment item of the Clinical Global Impressions scale (CGI-I), a widely used categorical measure of treatment response in which responders are defined as having a change item score of 1 = "very much" or 2 = "much" improved (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>
<B>)</B>. Symptom severity was assessed by measures such as the Hamilton Anxiety Scale (HAM-A) for generalised anxiety disorder (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>), the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (<LINK REF="REF-Goodman-1989" TYPE="REFERENCE">Goodman 1989</LINK>), the Panic Disorder Severity Scale (PDSS) (<LINK REF="REF-Shear-1997" TYPE="REFERENCE">Shear 1997</LINK>), the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) (<LINK REF="REF-Blake-1990" TYPE="REFERENCE">Blake 1990</LINK>) and the Liebowitz Social Anxiety Scale (LSAS) (<LINK REF="REF-Liebowitz-1987" TYPE="REFERENCE">Liebowitz 1987</LINK>). </P>
<P>
<B>Secondary outcomes </B>
<BR/>Scores on symptom rating scales for disorders, other than the primary anxiety disorder, included:</P>
<P>(a) Depression symptom severity scales, such as the Hamilton Depression scale (HAM-D) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>). <BR/>(b) Anxiety symptom severity scales, such as the Hamilton Anxiety scale (HAM-A) (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>).</P>
<P>The effectiveness of medication was also assessed through measurement of: </P>
<P>(a) Functional disability, such as the Sheehan Disability Scale (SDS), which included subscales to assess work, social and family related impairment (<LINK REF="REF-Sheehan-1996" TYPE="REFERENCE">Sheehan 1996</LINK>).<BR/>(b) Quality of life, such as the SF-36 Health Survey (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>).<BR/> <BR/>Finally, the acceptability of medication was determined by: </P>
<P>(a) Calculating the proportion of participants who withdrew from the interventions due to adverse events. This was included in the analysis as a surrogate measure of medication acceptability, in the absence of other more direct indicators of acceptability. <BR/>(b) A narrative review of significant differences between the medication and control groups in the prevalence of the most common drug-related adverse events (defined as occuring in at least 20% of the participants given medication, on the basis of the typically small sample sizes employed) for both trials included and excluded from the quantitative analyses. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>
<BR/>Electronic Searches<BR/>
</B>
<BR/>(1) The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References),</P>
<P>
<B>CCDANCTR-Studies </B>(searched on 3/8/2005)<BR/>Diagnosis = Anxiety or Anxious or Agoraphobia or "Phobic Disorder*" or "Panic Disorder" or "Obsessive Compulsive Disorder" or "Post-Traumatic Stress Disorders"<BR/>and<BR/>Free-text = (Augment*</P>
<P>
<B>CCDANCTR-References</B> (searched on 3/8/2005)<BR/>Keywords = Anxiety or Panic or Phobi* or Obsessive or Compulsive or "Post-Traumatic"<BR/>and<BR/>Free-text = refract* or resistant* or non-respond* or unrespons* or fail* or augment* or potentiation or combin*</P>
<P>(2) Additional searches were carried out on MEDLINE (via PubMed, 1966 to July 2005) and PsycINFO (1972 to 2005 PART A).</P>
<P>The complete MEDLINE search query, as derived from the search strategy developed by Robinson and Dickersin (2002), is provided below:</P>
<P>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ("latin square" [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) AND (anxiety disorder [mh:noexp] OR "anxiety disorder" [tw] OR phobic disorders [mh:noexp] OR obsessive-compulsive disorder [mh] OR "obsessive-compulsive" [tw] OR stress disorders, post-traumatic [mh:noexp] OR "post-traumatic" [tw]) AND (augmentation [tw] OR "treatment-refractory" [tw] OR refractory [tw] OR treatment-resistan* [tw] OR Drug Resistance [mh]) </P>
<P>The PsycINFO search strategy included the following search query: (("randomisation" or "randomization") or "controlled") and ("drug" or medic*) and ("augmentation" or "refractory" or resistan* ) and "anxiety". PsycINFO includes the Dissertational Abstracts International database - a database of unpublished dissertations.</P>
<P>(3) Ongoing trials were located using the meta Register of Controlled Trials database (mRCT) (http://www.controlled-trials.com) as well as the National Institute of Health's Computer Retrieval of Information on Scientific Projects (CRISP) service (1972 to 2005). The search terms "(augmentation OR resistant OR resistance) AND anxiety" and "(anxiety AND treatment-resistance)" were entered into the search interfaces for these databases, respectively.</P>
<P>
<B>Reference Lists<BR/>
</B>Additional RCTs were sought in reference lists of the retrieved articles.</P>
<P>
<B>Correspondence<BR/>
</B>(1) Attempts were made to obtain published and unpublished trials from key researchers, as identified by the frequency with which they are cited in the bibliographies of RCTs and open-label studies.</P>
<P>(2) Pharmaceutical companies were also contacted. They were identified through the source of funding cited in published RCTs. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>
<BR/>Selection of studies</B>
<BR/>RCTs were independently identified and assessed for inclusion by two raters (JI &amp; NF), based on information included in the abstract and/or main body of the trial report. Both raters independently collated data from RCTs that they regarded as satisfying the inclusion criteria for this review. Any disagreements in assessment and collation were resolved by discussion with a third reviewer (DS). </P>
<P>
<B>Data extraction and management<BR/>
</B>Spreadsheet forms were designed for the purpose of recording descriptive information, as well as the summary statistics of the outcome measures, the quality scale ratings and associated commentary. The data were subsequently exported to the Review Manager (RevMan) software, which was used to conduct the meta-analysis. The reviewers contacted investigators by email in an attempt to obtain missing information. In this review, one of the reviewers assessed the quality of the trials by means of the CCDAN Quality Rating Scale (CCDAN-QRS) (<LINK REF="REF-Moncrieff-2001" TYPE="REFERENCE">Moncrieff 2001</LINK>).</P>
<P>The following information was collated from each trial:</P>
<P>(a) Description of the trials, including whether it was industry funded, the primary researcher and year of publication</P>
<P>(b) Characteristics of the interventions, including the number of participants randomised to the treatment and control groups, the number of total drop-outs per group, as well as those who dropped out due to drug-related adverse events, the dose of medication and the period over which it was administered, the name of the medication, and the class to which it belongs (SSRIs, TCAs, MAOIs, antipsychotics, benzodiazepines, and "Other medication"). </P>
<P>(c) Characteristics of trial methodology, including the diagnostic (eg DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)) and exclusionary criteria employed, the screening instrument used (eg the Mini-International Neuropsychiatric Interview (MINI) (<LINK REF="REF-Lecrubier-1997" TYPE="REFERENCE">Lecrubier 1997</LINK>)) for both the primary diagnosis and comorbidity, the use of a placebo run-in and a minimal severity criterion, the number of centres involved and the trial's quality score on the CCDAN Quality Rating Scale.</P>
<P>(d) Characteristics of participants, including their gender distribution, mean age, age range, the mean length of time that they have been diagnosed with the disorder, the total number of medications with which they have been treated in the past for the disorder and whether they have previously been exposed to medication belonging to the same class as the current augmentation agent (treatment naivety), the number of participants in the sample with MDD, the number of participants presenting with motor or vocal tics and the baseline severity of the anxiety disorder, as assessed by the trial's primary outcome measure or another commonly employed scale. </P>
<P>(e) Outcome measures employed (primary and secondary), and summary continuous and dichotomous data. Data from continuous outcome measures consisted of the baseline and endpoint means and standard deviations for the medication and comparator groups, or change scores if endpoint data were not available, while the number of responders in these groups were recorded for dichotomous outcomes. Additional information included whether data reflected the intention-to-treat (ITT) with last observation carried forward (LOCF) or mixed methods (MM) sample, or whether a completer/observed cases (OC) sample was reported. </P>
<P>(f) Quality assessment, including the number of randomised participants who were not included in the analysis (lost to follow-up (LTF)), whether blinding occurred for the assessor/s, patients, or those who administered medication, as well as whether the allocation of medication was randomised and the allocation sequence was concealed (the methods used in implementing these respective bias reduction measures were also documented).</P>
<P>
<B>Assessment of methodological quality of included studies<BR/>
</B>There has been some debate how best to measure the quality of trials, and further work in this area remains necessary (<LINK REF="REF-Berlin-1999" TYPE="REFERENCE">Berlin 1999</LINK>). In this review, one of the reviewers assessed the quality of the trials by means of the CCDAN Quality Rating Scale<B> </B>(CCDAN-QRS) (<LINK REF="REF-Moncrieff-2001" TYPE="REFERENCE">Moncrieff 2001</LINK>) (http://www.iop.kcl.ac.uk/IoP/ccdan/qrs.htm). This 23 item scale assesses a range of features such as sample size, the duration of the intervention, inclusion and exclusion criteria and whether or not the power of the trial to detect a treatment effect was calculated. In addition, data for other trial characteristics that have been recognised as potential sources of bias, such as the method used in generating the allocation sequence, how allocation was concealed, whether outcome assessment was blinded, and the number of participants who where lost to follow up, were independently determined by two raters, as part of the data collation process. This is regarded as necessary given doubts concerning the usefulness of an overall quality score from a scale composed of multiple items (<LINK REF="REF-Alderson-2003" TYPE="REFERENCE">Alderson 2003</LINK>). </P>
<P>
<B>Measures of treatment effect<BR/>
</B>
<BR/>
<B>Dichotomous data<BR/>
</B>Relative risk (RR), together with its 95% confidence intervals (CI), was used as the summary statistic for the primary dichotomous outcome of interest (CGI-I), given the common occurrence of the adverse outcome of interest (more than 20%), and the greater ease of interpreting this statistic compared to the odds ratio. Where data were available, RR was also used for other dichotomous outcomes of interest.</P>
<P>
<B>Continuous data<BR/>
</B>Weighted mean differences (WMD) with 95% CIs were calculated for continuous summary data obtained from studies employing identical scales. Alternatively, in cases in which different scales are used to determine the same outcome, or in which different versions of the same scale are employed, the standardised mean difference was determined. This method of analysis standardises the differences between the means of the treatment and control group in terms of the variability observed in the trial.</P>
<P>
<B>Studies with multiple treatment groups<BR/>
</B>In the case of data from trials employing multiple fixed doses of medication, the bias introduced through comparing the summary statistics for multiple groups against the same placebo control was avoided by pooling the means and standard deviations across all of the treatment arms as a function of the number of participants in each arm (see <LINK REF="REF-Law-2003" TYPE="REFERENCE">Law 2003</LINK>). The total mean and standard deviation for the medication agent, calculated as the sum total of the weighed contribution from each medication arm, was then compared to the unadjusted statistics for the control group. The same concerns regarding the introduction of bias led to the decision to limit outcome comparisons in trials which compare the efficacy of multiple forms of medication with that of placebo to one of the medication groups. The reviewers selected the medication group to include in the comparison (prior to analysis, to avoid introducing bias) on the basis of which of the medication classes are least well represented. Efficacy data on head-to-head comparisons of medication will be reported in a separate comparison, where available. </P>
<P>
<B>Cross-over trials<BR/>
</B>Cross-over trials were only included in the calculation of summary statistics when it was (a) possible to extract medication and placebo/comparator data from the first treatment period, or (b) when the inclusion of data from both treatment periods was justified through a wash-out period of sufficient duration as to minimise the risk of carry-over effects. The minimum wash-out period required was assessed on the basis of the plasma half-life of the particular agent, as determined by consulting the Lundbeck Psychotropics website (<LINK REF="REF-Lundbeck-2003" TYPE="REFERENCE">Lundbeck 2003</LINK>). <BR/>
<B>
<BR/>
</B>For cross-over trials in which the washout period was regarded as adequate, data from both periods were only included when it was possible to determine the standard error of the mean difference in response between groups (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). The summary statistics required to derive the standard error of interest were obtained from the trial report, or for trials for which this information was missing, were imputed through averaging the relevant statistic from other included crossover trials with comparable control conditions. A narrative review was conducted of the findings of cross-over trials which met neither criteria.</P>
<P>
<B>Dealing with missing data</B>
<BR/>All analyses of dichotomous data were intention-to-treat (ITT). The total number of participants randomised to the different comparison groups was used as the denominator in comparisons of treatment response. Only data from trials which provide information on the original group size (prior to drop-outs) were included in the analyses of treatment response. Preference was given to the inclusion of summary statistics for continuous outcome measures derived from mixed effects models, followed by last observation carried forward (LOCF) and observed cases (OC) summary statistics (in that order). This is in line with evidence that ME methods are more robust to bias than LOCF analyses (<LINK REF="REF-Verbeek--2000" TYPE="REFERENCE">Verbeek 2000</LINK>). </P>
<P>
<B>Assessment of heterogeneity</B>
<BR/>Heterogeneity of treatment response, that is whether the differences between the results of trials were greater than would be expected by chance alone, was assessed visually from the forest plot of relative risk. It was also determined by means of the chi-squared test of heterogeneity, with a significance level of less than 0.10 interpreted as evidence of heterogeneity, given the low power of the chi-squared statistic when the number of trials is small (<LINK REF="REF-Deeks-2005" TYPE="REFERENCE">Deeks 2005</LINK>). <BR/> <BR/>In addition, the I-square heterogeneity statistic reported by RevMan was used to test the robustness of the chi-squared statistic to differences in the number of trials included in the groups being compared within each subgroup analysis (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Differences on continuous measures in medication efficacy between these groups were assessed by means of Deeks' stratified test of heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). This method subtracts the sum of the chi-squared statistics for each of the groups from the total chi squared for the subgroup analysis, to provide a measure (Q<SUB>b</SUB>) of heterogeneity between groups. Differences in treatment response on the CGI-I were determined by whether the confidence intervals of the subgroups overlaped. This method was chosen in preference to the stratified test, due to inaccuracies in the calculation in RevMan of the chi-squared statistic for dichotomous measures (<LINK REF="REF-Deeks-2005" TYPE="REFERENCE">Deeks 2005</LINK>). </P>
<P>
<B>Assessment of reporting bias<BR/>
</B>
<BR/>
<B>Publication bias <BR/>
</B>Publication bias was<B> </B>determined by visual inspection of a funnel plot of treatment response. <B> </B>A more objective measure of bias for treatment response was obtained by regressing the standardised treatment effects for the RCTs on the inverse of the standard error of their treatment estimate (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). This procedure was performed using the meta package of the R statistical language (<LINK REF="REF-R-2005" TYPE="REFERENCE">R 2005</LINK>).</P>
<P>
<B>Data synthesis (meta-analysis)<BR/>
</B>A random-effects model was employed for the analysis of both dichotomous and continuous outcome measures. As this model included both within-study sampling error and between-studies variation, there was less risk of committing a Type I error (falsely concluding that there is a treatment effect when there is none) through overestimating the precision of effect size estimates, than would be the case were the fixed-effect model employed (<LINK REF="REF-Hunter-2000" TYPE="REFERENCE">Hunter 2000</LINK>). </P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>
<BR/>Subgroup analyses were undertaken in order to assess systematic differences across studies on both primary outcome measures, number of trials permitting. Trials were grouped according to the following methodological criteria:</P>
<UL>
<LI> The involvement of participants from a single centre or multiple centres. Single centre trials were more likely to be associated with lower sample size but less variability in clinician ratings.</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI> Whether or not trials were industry funded. In general, published trials which were sponsored by pharmaceutical companies were more likely to report positive findings than trials that were not supported by for-profit companies (<LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>; <LINK REF="REF-Baker-2003" TYPE="REFERENCE">Baker 2003</LINK>).</LI>
</UL>
<P> <BR/>In addition, the following criteria were used to assess the extent of clinical sources of heterogeneity:</P>
<UL>
<LI> Whether or not the sample included patients diagnosed with major depression. This may assist in determining the extent to which the efficacy of a medication agent in treating anxiety disorders is independent of its ability to reduce symptoms of depression, an important consideration given the possibility that augmenting agents may potentiate the antidepressant qualities of the first-line medication agents. </LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI> Whether patients had been exposed to medication of a sufficient dosage and duration to confirm treatment resistance. A review of the treatment of panic disorder found that as many as 76% of trials of antipanic medications were inadequate in dose and duration (<LINK REF="REF-Cowley-1997" TYPE="REFERENCE">Cowley 1997</LINK>). For purposes of consistency, definitions of adequate duration and dosage were determined according to expert consensus. This consensus was taken from clinical practice guidelines (<LINK REF="REF-BAP-2005" TYPE="REFERENCE">BAP 2005</LINK>; <LINK REF="REF-WFSBP-2002" TYPE="REFERENCE">WFSBP 2002</LINK>), as well as from <LINK REF="REF-Pallanti-2002" TYPE="REFERENCE">Pallanti 2002</LINK> in the case of treatment-resistant OCD. </LI>
</UL>
<P>
<BR/>
<B>Sensitivity analyses<BR/>
</B>Sensitivity analyses determine the robustness of the reviewer's conclusion to methodological assumptions made in conducting the meta-analysis. A sensitivity analysis was planned to determine whether treatment response varies as a function of: </P>
<UL>
<LI>The use of treatment response versus non-response as a summary statistic. This comparison was regarded as potentially important given evidence that treatment response may have resulted in less consistent summary statistics than non-response (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>) when the control group adverse event rate (defined as non-response to treatment) was below 50% . </LI>
</UL>
<P>
<B>
<BR/>
</B>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>
<BR/>Results of the search</B>
<BR/>The search of the CCDAN Controlled Trials Register yielded four studies, of which one was included in the review. The PubMed search retrieved a total of 292 articles, 17 of which were eligible for inclusion in this review. The search of PsycINFO yielded 50 references, three of which were included in the review. The search for unpublished trials resulted in the retrieval of 14 and 385 documents from the mRCT and CRISP databases, respectively.</P>
<P>
<B>Included studies</B>
<BR/>A total of 28 short-term randomised controlled trials (740 participants) were included in the review. The trials lasted for seven weeks on average (excluding cross-over studies), with only three of the trials continuing for 12 weeks or longer (<LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>; <LINK REF="STD-Fineberg-2005" TYPE="STUDY">Fineberg 2005</LINK>; <LINK REF="STD-Pallanti-1999" TYPE="STUDY">Pallanti 1999</LINK>). Over two thirds of the trials (N = 20) investigated augmentation of treatment-resistant obsessive compulsive disorder (OCD). The remaining RCTs examined the efficacy of augmentation medication for treatment-resistant post-traumatic stress disorder (PTSD) (N = 4), generalised anxiety disorder (GAD) (N = 2), panic disorder (PD) (N = 1), and social anxiety disorder (SAD) (N = 1). Only two of these trials did not employ a placebo control, both administering an active medication as control for the treatment of resistant OCD patients (<LINK REF="STD-Pallanti-1999" TYPE="STUDY">Pallanti 1999</LINK> investigated the efficacy of the tricyclic clomipramine in augmenting citalopram, and <LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK> compared the efficacy of lithium and triiodothyronine in the augmentation of clomipramine). Six of the trials employed a crossover design (<LINK REF="STD-Fux-1999" TYPE="STUDY">Fux 1999</LINK>; <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>; <LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>; <LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>; <LINK REF="STD-Stein-2001" TYPE="STUDY">Stein 2001</LINK>). All but one of the trials (<LINK REF="STD-Pollack-2006" TYPE="STUDY">Pollack 2006</LINK>) were published, and all of these publications were in English.</P>
<P>Of the included trials, only a quarter (7/28) contained patients described as resistant to ongoing treatment with agents other than SRIs (with one of the trials merely describing ongoing medication as including antidepressants (<LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>)). Eleven trials included patients who were resistant to a current treatment regime of both SSRIs and other medications, including clomipramine (N = 5), as well as anticonvulsants, antipsychotics, azapirones, benzodiazepines, TCAs, lithium and buproprion (N = 6). The agents most commonly tested as part of an augmenting regime were the antipsychotic medications, with treatment arms including both first generation (N = 2: 2 haloperidol) and second generation antipsychotics (N = 15: 4 olanzapine, 4 quetiapine, 7 risperidone). RCTs of other augmentation medications included three trials of the beta-blocker, pindolol, and a single trial of the TCA, desipramine. Of the seven studies of agents classified as "Other medications", five of the trials examined individual agents (one buspirone, one clomipramine, one inositol, one lithium, one prazosin), while two crossover trials compared multiple medications (one lithium and triiodothyronine, one morphine and lorazepam).</P>
<P>
<B>Trials excluded from the review</B>
<BR/>The most common reasons for excluding trials from the review were failure to restrict participation to treatment-resistant patients in augmentation trials (<LINK REF="STD-Grady-1993" TYPE="STUDY">Grady 1993</LINK>; <LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>; <LINK REF="STD-Mundo-1998" TYPE="STUDY">Mundo 1998</LINK>; <LINK REF="STD-Pallanti-2004" TYPE="STUDY">Pallanti 2004</LINK>; <LINK REF="STD-Pollack-2003" TYPE="STUDY">Pollack 2003</LINK>) and the failure to employ an augmentation strategy in treating resistant patients (<LINK REF="STD-Denys-2004b" TYPE="STUDY">Denys 2004b</LINK>; <LINK REF="STD-Fallon-1998" TYPE="STUDY">Fallon 1998</LINK>). Other reasons for excluding trials included the failure to randomly allocate patients to the medication and placebo groups (<LINK REF="STD-Pigott-1992" TYPE="STUDY">Pigott 1992</LINK>) and the concurrent treatment of participants with augmentation medication and psychotherapy (<LINK REF="STD-Otto-2003" TYPE="STUDY">Otto 2003</LINK>).</P>
<P>
<B>Trials excluded from quantitative analyses</B>
<BR/>Five parallel trials were excluded from the meta-analyses due to failure to provide sufficient information on a standardised scale to determine whether the samples were treatment resistant (<LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>, <LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>; <LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>; <LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>; <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>). In addition, <LINK REF="STD-Shapira-2004" TYPE="STUDY">Shapira 2004</LINK> was excluded, as treatment resistance was defined in this trial as an absolute score on an assessment scale, rather than a relative improvement between baseline and endpoint. <LINK REF="STD-Barr-1997" TYPE="STUDY">Barr 1997</LINK> did not provide adequate information for inclusion in the outcome comparisons.</P>
<P>Cross-over trials were not included in the quantitative analyses, due to a number of methodological shortcomings. Neither <LINK REF="STD-Fux-1999" TYPE="STUDY">Fux 1999</LINK> nor <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK> provided sufficient information to determine whether their samples were treatment-resistant. <LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK> required that patient scores on the Y-BOCS decreased by at least 15% before they were eligible for inclusion in the augmentation phase of the trial. Both <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK> and <LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK> failed to define treatment resistance in terms of relative improvement following treatment, with six of the 23 participants in the former RCT not receiving treatment with concurrent psychotropics during the augmentation phase of the trial. <LINK REF="STD-Stein-2001" TYPE="STUDY">Stein 2001</LINK> did not provide sufficient data for inclusion in the outcome comparisons.</P>
<P>
<B>Ongoing studies</B>
<BR/>The search of the CRISP database retrieved a single ongoing trial of prazosin augmentation of SSRIs in treatment-resistant non-combat related PTSD (<LINK REF="STD-Raskind-2006" TYPE="STUDY">Raskind 2006</LINK>), as well as a trial of clonazepam augmentation of sertraline-resistant panic disorder (<LINK REF="STD-Simon-2006" TYPE="STUDY">Simon 2006</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>
<BR/>Generation of Allocation Sequence<BR/>
</B>A description of the randomisation procedure employed was provided in four trials. Computer generated random codes were employed in three of these trials (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>; <LINK REF="STD-Erzegovesi-2004" TYPE="STUDY">Erzegovesi 2004</LINK>; <LINK REF="STD-McDougle-2000" TYPE="STUDY">McDougle 2000</LINK>) while a pharmacist used a balanced randomisation procedure in the fourth (<LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>).</P>
<P>
<B>Allocation Concealment</B>
<BR/>Of the 28 short-term RCTs, only three described the allocation sequence that was used in assigning participants to the treatment and comparison groups. Adequate allocation concealment was practiced in two trials (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>; <LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK>), while the remaining trial did not provide sufficient information to determine the adequacy of the concealment used (<LINK REF="STD-Erzegovesi-2004" TYPE="STUDY">Erzegovesi 2004</LINK>). The trial of clomipramine augmentation of citalopram for resistant OCD did not practice any form of treatment concealment (<LINK REF="STD-Pallanti-1999" TYPE="STUDY">Pallanti 1999</LINK>).</P>
<P>
<B>Blinding of Outcome Assessment<BR/>
</B>Outcome assessment was explicitly described as blinded in 10 of the short term trials (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>; <LINK REF="REF-Denys-2004c" TYPE="REFERENCE">Denys 2004c</LINK>; <LINK REF="STD-Erzegovesi-2004" TYPE="STUDY">Erzegovesi 2004</LINK>; <LINK REF="STD-Hollander-2003" TYPE="STUDY">Hollander 2003</LINK>; <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>; <LINK REF="STD-McDougle-1991a" TYPE="STUDY">McDougle 1991a</LINK>; <LINK REF="STD-McDougle-1991b" TYPE="STUDY">McDougle 1991b</LINK>; <LINK REF="STD-McDougle-1994" TYPE="STUDY">McDougle 1994</LINK>; <LINK REF="STD-McDougle-2000" TYPE="STUDY">McDougle 2000</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>). Reference was made to the blinding of raters to medication side-effects in only two trials (<LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>; <LINK REF="STD-McDougle-1994" TYPE="STUDY">McDougle 1994</LINK>). </P>
<P>
<B>Loss to follow up</B>
<BR/>An average of 18.2% of the trial participants did not reach study endpoint. Seven of the 20 trials that provided drop-out data lost more than a quarter of the sample during the course of the trial<B> </B>(<LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>; <LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>; <LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>; <LINK REF="STD-Pollack-2006" TYPE="STUDY">Pollack 2006</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>; <LINK REF="STD-Stein-2001" TYPE="STUDY">Stein 2001</LINK>; <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>). <B>
<BR/>
</B>
<BR/>
<B>Quality Score<BR/>
</B>The average quality score on the CCDAN-QRS for the short term trials was 23 (range 16 to 31) out of a maximum of 48 points. On this scale, 23 of the 28 trial reports provided inadequate details of the side-effects experienced by each group, 17 failed to either provide a record of the exclusion criteria used or to report the number of people excluded by these criteria, and eight did not provide information about funding.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Approximately half of the RCTs (13/27) could not be included in the quantitative analysis, for a variety of reasons (see "Trials excluded from quantitative analyses" above). The reviewers decided, on the basis of the number of trials employing antipsychotics as augmenting agents, to conduct additional post-hoc efficacy analyses by individual agents within this class. <BR/>
<B>
<BR/>Primary outcome measures</B>
</P>
<P>
<B>Treatment response</B>
<BR/>All of the trials included in the treatment response comparison were of OCD. Augmentation with medication was significantly more likely to result in treatment response than placebo (number of trials (N) = 9, relative risk of response (RR) 3.16, 95% CI 1.08 to 9.23, sample size (n) = 250), as determined by the CGI-I. Response occurred in more than twice as many patients treated with medication (31.8%) than with placebo (13.6%). A number needed to treat (NNT) of 5.5 indicated that it would take approximately six additional patients on an augmentation agent for this difference in efficacy to translate into one extra treatment responder, relative to placebo. </P>
<P>Evidence for the efficacy of the antipsychotics as a group in increasing response rates in OCD trials was ambigious (N = 6, RR 3.55, 95% CI 0.99 to 12.72, n = 187). This finding was attributable, in part, to the presence of an unusually high placebo response rate (12/21) in one of the quetiapine trials (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>). A significantly higher treatment response was observed following the post-hoc removal of this trial from the comparison (N = 5, RR 5.43, 95% CI 2.13 to 13.87, n = 146). In the only trial which was not included in the meta-analysis but does provide data on the number of responders on the CGI-I, neither olanzapine nor risperidone was reported as demonstrating superiority over placebo in augmenting medication for PTSD (<LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>) or generalised anxiety disorder (<LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>), respectively.<BR/> <BR/>
<B>Reductions in symptom severity</B>
<BR/>Overall symptom severity was reduced to a greater extent in the medication than the control groups (N = 14, standardised mean difference (SMD) -0.87, 95%CI -1.37 to -0.36, n = 337). </P>
<P>
<B>Obsessive compulsive disorder</B>
<BR/>A significant effect of medication was observed for the treatment of resistant OCD (N = 12, SMD -0.66, 95%CI -1.12 to -0.19, n = 291). Evidence of efficacy in treating this disorder was observed for the antipsychotics (N = 7, SMD -0.68, 95% CI -1.13 to -0.24, n = 198), but not for the trials of lithium (<LINK REF="STD-McDougle-1991a" TYPE="STUDY">McDougle 1991a</LINK>; <LINK REF="STD-McDougle-1991b" TYPE="STUDY">McDougle 1991b</LINK>) or buspirone (<LINK REF="STD-McDougle-1993" TYPE="STUDY">McDougle 1993</LINK>). The single trials of the beta-blocker pindolol (<LINK REF="STD-Dannon-2000" TYPE="STUDY">Dannon 2000</LINK>) and the tricyclic clomipramine (<LINK REF="STD-Pallanti-1999" TYPE="STUDY">Pallanti 1999</LINK>) both found positive effects for medication in reducing symptom severity, with efficacy also observed for risperidone (N = 3, SMD -0.63, 95% CI -1.12 to -0.14, n = 69) and quetiapine (N = 4, SMD -0.77, 95% CI -1.52 to -0.02, n = 129) in a post-hoc analysis of individual antipsychotic agents. </P>
<P>The finding of a positive effect of medication on symptom severity was supported by many of the trials which were not included in the meta-analysis. A significant reduction in the severity of obsessive symptoms on the total Y-BOCS scale was reported in a trial of the first generation antipsychotic haloperidol for 16 OCD patients resistant to 12 weeks of treatment with an SSRI (<LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>). Notably, risperidone was found to be less effective than haloperidol in ameliorating OCD symptoms in this study, though it was significantly more effective in reducing symptoms of depression. The addition of olanzapine to participants with OCD unresponsive to at least 12 weeks SSRI or clomipramine treatment resulted in a significant reduction of symptom severity on the Y-BOCS for the last observation carried forward sample (N = 26, P = 0.4), but not for the observed cases sample (N = 18, P = 0.9) (<LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>). Augmentation of fluoxetine with olanzapine for a period of six weeks failed to demonstrate superiority over placebo on Y-BOCS scores for 44 participants with OCD (<LINK REF="STD-Shapira-2004" TYPE="STUDY">Shapira 2004</LINK>). </P>
<P>Neither adjuvant lithium nor triidothyronine was observed to result in significant improvements on the Y-BOCS relative to placebo for 16 OCD patients in a cross-over trial who had been administered a steady dose of clomipramine for a period of six months (<LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK>). The carbohydrate inositol failed to demonstrate superiority to placebo in reducing symptom severity on the Y-BOCS amongst 10 OCD patients who were treated for six weeks in a cross-over trial (<LINK REF="STD-Fux-1999" TYPE="STUDY">Fux 1999</LINK>). The TCA desipramine was no more efficacious than placebo in reducing symptom severity on the Y-BOCS amongst 30 OCD non-responders to treatment with SSRIs, following a period of at least 10 weeks (<LINK REF="STD-Barr-1997" TYPE="STUDY">Barr 1997</LINK>). Finally, <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK> described a significant reduction of Y-BOCS scores amongst 23 OCD patients following a placebo-controlled two week cross-over administration of SRI's augmented with morphine, but not lorazepam.</P>
<P>
<B>Generalised anxiety disorder</B>
<BR/>The antipsychotic olanzapine resulted in significantly less severe symptoms of generalised anxiety disorder on the HAM-A in the only trial of this disorder included in the meta-analysis (SMD -0.98, 95%CI -1.9 to -0.05, n = 21). This finding was replicated for another antipsychotic in a five week controlled trial of risperidone for 39 participants diagnosed with GAD (<LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>). </P>
<P>
<B>Panic disorder</B>
<BR/>The beta-blocker pindolol was effective in reducing symptom severity (SMD -3.73, 95%CI -5.1 to -2.36, n = 25) in the only medication augmentation trial of medication for panic disorder to be included in the meta-analyses. </P>
<P>
<B>Post-traumatic stress disorder</B>
<BR/>No trials of PTSD could be included in the meta-analysis. Of those trials that were excluded, prazosin was reported in a cross-over study as demonstrating significant reductions on the CAPS for 10 combat veterans who were being treated concurrently with a variety of medications (<LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>). <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK> also observed greater reductions in CAPS following eight weeks augmentation with olanzapine versus placebo in combat-related PTSD participants (N = 19) who had failed to respond adequately to at least 12 weeks of an SSRI. In a 16 week trial of adjunctive risperidone for combat-related PTSD patients who were resistant to treatment with various anxiolytics, antidepressants and hypnotics, <LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK> observed significant effects for medication compared to placebo on total and hyperarousal subscale scores of the CAPS symptom severity scale. Conversely, risperidone failed to demonstrate greater efficacy than placebo over a period of five weeks on the total CAPS scores in a sample of 37 PTSD patients with comorbid psychosis (<LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>). </P>
<P>
<B>Social anxiety disorder</B>
<BR/>No trials of social anxiety disorder could be included in the meta-analysis. Cross-over potentiation of paroxetine with pindolol over a period of 12 weeks was reported as not being more effective than placebo for 14 patients diagnosed with treatment resistant generalised social anxiety disorder (GSAD) (<LINK REF="STD-Stein-2001" TYPE="STUDY">Stein 2001</LINK>). </P>
<P>
<B>Secondary outcome measures</B>
</P>
<P>
<B>Symptom rating scales for disorders secondary to the primary anxiety disorder</B>
<BR/>No reduction in comorbid symptoms of depression were observed for the 13 trials which provide summary statistics for this outcome (SMD -0.23, 95%CI -0.7 to 0.23, n = 310). The same is true for anxiety symptoms assessed using the Hamilton Anxiety Rating Scale (N = 7, SMD = -1.33, 95%CI = -4.69, 2.03, n = 175). The findings of the majority of the trials which were not included in the meta-analysis were consistent with those which were included, with no differences in outcome observed between medication and control groups for symptoms of depression (<LINK REF="STD-Barr-1997" TYPE="STUDY">Barr 1997</LINK>; <LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>; <LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>; <LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>; <LINK REF="STD-Fux-1999" TYPE="STUDY">Fux 1999</LINK>; <LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>; <LINK REF="STD-Pigott-1991" TYPE="STUDY">Pigott 1991</LINK>) or anxiety (<LINK REF="STD-Barr-1997" TYPE="STUDY">Barr 1997</LINK>; <LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>; <LINK REF="STD-Bystritsky-2004" TYPE="STUDY">Bystritsky 2004</LINK>; <LINK REF="STD-Fux-1999" TYPE="STUDY">Fux 1999</LINK>). Risperidone was significantly more effective in reducing depressive symptoms in patients with OCD than either haloperidol or placebo, while both medications reduced anxiety as assessed by the Hopkin's Symptom's Checklist (<LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>). </P>
<P>
<B>Other measurements of medication effectiveness</B>
<BR/>Functional disability was not noticeably improved by pharmacotherapy augmentation in a small sub-group of studies (N = 3, WMD -1.18, 95%CI -2.55 to 0.19, n = 102), according to summary statistics on the Sheehan Disability Scale (SDS). None of the trials included in this review reported outcomes on quality of life measures, though <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK> described improved quality of sleep amongst patients with resistant combat-related PTSD who completed eight weeks of SSRI augmentation with olanzapine. </P>
<P>
<B>Acceptability of medication</B>
<BR/>There is no evidence of a difference between medication and placebo in rate of drop-out due to treatment emergent adverse events (N = 9, RR 2.16, 95% CI 0.64 to 7.28, n = 241). This was despite the fact that four of the trials were not included in the calculation of the overall summary statistic due to a zero drop-out rate for both medication and control groups. </P>
<P>The most frequent side-effect observed for all of the antipsychotic agents was sedation/somnolence, experienced by 20% or more of the participants receiving medication in 11 of the 14 trials in the review providing data on medication tolerance. Somnolence led to the withdrawal of nine (69.2%) of the 13 patients who were reported as dropping out of antipsychotic augmentation trials as a result of drug-related adverse events. Other side-effects commonly associated with antipsychotic augmentation included weight gain, nausea, dizziness, dry mouth, gastrointestinal distress and increased appetite. Addition of the SNRI clomipramine resulted in significantly greater rates of dry mouth, constipation, delayed orgasm and blurred vision (<LINK REF="STD-Pallanti-1999" TYPE="STUDY">Pallanti 1999</LINK>), while an increased incidence of sedation, dizziness, and nausea was observed with morphine augmentation and sedation and fatigue with the addition of lorazepam (<LINK REF="STD-Koran-2005" TYPE="STUDY">Koran 2005</LINK>). In the direct comparison of the typical antipsychotic haloperidol, and the atypical antipsychotic risperidone, five of the 12 resistant OCD participants discontinued haloperidol treatment due to dystonia or severe lethargy, while no withdrawals were reported for the risperidone arm of the crossover trial (<LINK REF="STD-Li-2005" TYPE="STUDY">Li 2005</LINK>). </P>
<P>
<B>Heterogeneity</B>
<BR/>A substantial degree of heterogeneity was observed for both treatment response (chi squared = 17.44, P = 0.01) and symptom severity outcome measures (chi squared = 36.78, P &lt; 0.01). This finding was corroborated by the high total I-square statistic in both cases (59.9% and 67.4%, respectively). Heterogeneity in symptom severity was introduced through different classes of augmentation medication (Q<SUB>b</SUB> = 4.01, P = 0.05), but not differences in the efficacy of medication for different anxiety disorders (Q<SUB>b</SUB> = 0.78, P = 0.38). A post-hoc comparison revealed a significantly greater reduction of symptom severity across anxiety disorders for the combined data from two trials of the beta-blocker pindolol (n = 39) than was evident for the eight antipsychotic trials (n = 219).</P>
<P>Additional post-hoc analyses revealed significant variation in both treatment response and symptom severity reduction amongst the antipsychotic trials (chi squared = 15.68, P &lt; 0.01 and chi squared = 13.55, P = 0.06, respectively). There was, however, no evidence of differential efficacy of the individual antipsychotic agents on either treatment response or reduction in symptom severity. The exclusion of the trial with the highest placebo response rate (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>) reduced the heterogeneity of treatment response across all medication groups to non-significant levels (chi squared = 2.84, P = 0.83). </P>
<P>
<B>Subgroup analyses<BR/>
</B>None of the potential clinical and methodological sources of heterogeneity explained the variation between trials on treatment response (as determined by confidence interval overlap) or symptom severity. There was no evidence of the differential efficacy of medication in increasing rates of treatment response, or of medication reducing symptom severity, between trials grouped by source of funding (Q<SUB>b</SUB> = 0.12, P = 0.73), adequacy of dosage and treatment duration of the augmented medication (Q<SUB>b</SUB> = 1.35, P = 0.25) and inclusion of patients diagnosed with major depression (Q<SUB>b</SUB> = 0.61, P = 0.43) . The comparison of trials conducted at multiple versus single centres was not performed, as only a single trial (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>) could be classified in the former category. </P>
<P>A planned comparison to determine whether heterogeneity was caused by differences in treatment efficacy between treatment-refractory (showing no signs of response to several different treatment interventions) and treatment non-responsive (showing no signs of response to a single adequate medication trial) samples could not be performed, as none of the trials restricted inclusion to treatment-refractory patients. Instead, the reviewers decided, on the basis of the variation observed in the inclusion criteria employed in different trials, to conduct a post-hoc analysis to determine whether medication interventions were more efficacious in trials which restricted their samples to non-responders compared to trials which included partial responders. Partial responders were defined as those participants who total Y-BOCS score dropped between 25% and 35% of its baseline value, with non-responders' scores decreasing by less than 25% (<LINK REF="REF-Pallanti-2002" TYPE="REFERENCE">Pallanti 2002</LINK>). The 50% reduction on the HAM-A used as inclusion criteria for the single trial of generalised anxiety disorder (GAD) (<LINK REF="STD-Pollack-2006" TYPE="STUDY">Pollack 2006</LINK>) was considered adequate in screening out partial responders. The inclusion of partial responders (Qb = 0.91, P = 0.34) did not contribute appreciably to the heterogeneity in observed effect sizes.</P>
<P>
<B>Sensitivity analyses</B>
<BR/>It was decided not to conduct the sensitivity analysis of treatment response versus non-response, as more than 50% of the participants in the control groups failed to respond to treatment in the majority (8/9) of the trials providing data for inclusion in the meta-analysis. </P>
<P>
<B>Publication bias<BR/>
</B>Visual inspection of the funnel graphs for the treatment response and symptom severity scales revealed the possibility of publication bias (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). There is evidence of a bias towards the publication of small trials with statistically signficant results favouring the medication treatment on both treatment response and symptom severity, with the regression analysis revealing a significant degree of asymmetry for these outcomes (t = 2.55, P = 0.04 and t = -2.26, P = 0.04, respectively). The plots for the treatment response and symptom severity regression analyses can be found in the "additional figures" section (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, respectively).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The data suggested that short-term pharmacological augmentation of first-line drug treatments for anxiety disorders may be useful in some cases, with more than twice as many patients responding to treatment when active medication (31.8%) rather than placebo (13.6%) was provided as an augmentation agent. The number needed to treat (5.5) was also clinically acceptable. In addition, no evidence of a difference in drop-out rates in augmentation and control groups due to adverse events provides some evidence for the tolerability of this strategy. The limited evidence base failed, however, to demonstrate an improvement in overall functional disability following medication augmentation. </P>
<P>A large proportion of the evidence for the alleviation of anxiety disorder symptoms following medication augmentation was for SRI-resistant OCD, and the majority of this work was with antipsychotic agents. The sub-analysis of antipsychotics in OCD was significant for both risperidone and quetiapine, results that are consistent with open-label evidence for the effectiveness of the second-generation antipsychotics, including olanzapine (<LINK REF="REF-Bogetto-2000" TYPE="REFERENCE">Bogetto 2000</LINK>, <LINK REF="REF-D_x0027_Amico-2003" TYPE="REFERENCE">D'Amico 2003</LINK>, <LINK REF="REF-Francobandiera-2001" TYPE="REFERENCE">Francobandiera 2001</LINK>, <LINK REF="REF-Koran-2000" TYPE="REFERENCE">Koran 2000</LINK>; <LINK REF="REF-Weiss-1999" TYPE="REFERENCE">Weiss 1999</LINK>), quetiapine (<LINK REF="REF-Bogan-2005" TYPE="REFERENCE">Bogan 2005</LINK>; <LINK REF="REF-Denys-2002" TYPE="REFERENCE">Denys 2002</LINK>; <LINK REF="REF-Misri-2004" TYPE="REFERENCE">Misri 2004</LINK>) and risperidone (<LINK REF="REF-Arias-2002" TYPE="REFERENCE">Arias 2002</LINK>, <LINK REF="REF-Jacobsen-1995" TYPE="REFERENCE">Jacobsen 1995</LINK>; <LINK REF="REF-Pfanner-2000" TYPE="REFERENCE">Pfanner 2000</LINK>, <LINK REF="REF-Ravizza-1996" TYPE="REFERENCE">Ravizza 1996</LINK>, <LINK REF="REF-Saxena-1996" TYPE="REFERENCE">Saxena 1996</LINK>), as augmenting agents in the treatment of this disorder. The finding in this review of superior efficacy of pindolol to antipsychotics in augmentating resistant anxiety disorders should be interpreted cautiously, given its post-hoc nature and some inconsistent data (<LINK REF="STD-Stein-2001" TYPE="STUDY">Stein 2001</LINK>).<B> <BR/>
</B>
<BR/>There is less evidence for the efficacy of augmentation in anxiety disorders other than OCD. The trials of patients with SSRI-resistant generalised anxiety (<LINK REF="STD-Brawman-2004" TYPE="STUDY">Brawman 2004</LINK>; <LINK REF="STD-Pollack-2006" TYPE="STUDY">Pollack 2006</LINK>) and panic disorders (<LINK REF="STD-Hirschmann-2000" TYPE="STUDY">Hirschmann 2000</LINK>) suggested that augmentation strategies may be useful for these populations. Evidence from RCTs of the efficacy of augmentation agents in treating resistant PTSD (<LINK REF="STD-Bartzokis-2004" TYPE="STUDY">Bartzokis 2004</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>; <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>) must be regarded as preliminary, given doubts regarding the treatment resistant status of patients in these trials. </P>
<P>The substantial heterogeneity of treatment response and symptom severity across trials cannot be accounted for by the methodological (single versus multi-centre trials, industry versus non-industry funding, adequate versus inadequate dosage and duration of treatment with first-line agents) or clinical (presence versus absence of major depressive disorder, partial versus full non-response) differences between trials tested in this review. Medication class was the only study characteristic to mediate reductions in symptom severity, primarily due to the large positive effects of the beta-blocker pindolol in a small trial of treatment resistant OCD (<LINK REF="STD-Dannon-2000" TYPE="STUDY">Dannon 2000</LINK>). Inadequate reporting of sample characteristics and concerns regarding false positive outcomes due to multiple testing prohibited the investigation in this review of other factors which may have contributed to heterogeneity of treatment response, such as the number of previous medication interventions and baseline severity of the anxiety disorders.</P>
<P>Difficulty in the clinical application of this review's findings are compounded by variation in sample demographics, as well as a lack of consensus regarding the operational definition of treatment resistance (<LINK REF="REF-Pallanti-2002" TYPE="REFERENCE">Pallanti 2002</LINK>). Indeed, concerns about whether participants qualified as treatment-resistant resulted in the exclusion of nine RCTs from the meta-analyses conducted as part of this review. Although variability in the adequacy of prior medication treatment in the remaining trials did not contribute appreciably to differences in treatment effects across trials, none of the trials included investigated the efficacy of medication for treatment-refractory anxiety disorders (ie resistance to multiple concurrent medications). Controlled trials of the effectiveness of medication combinations that are commonly used by clinicians, such as the augmentation of SSRIs with clomipramine for OCD (<LINK REF="REF-Hollander-2002" TYPE="REFERENCE">Hollander 2002</LINK>) , and benzodiazepines for panic disorder (<LINK REF="REF-Bandelow-2004" TYPE="REFERENCE">Bandelow 2004</LINK>, <LINK REF="STD-Pollack-2003" TYPE="STUDY">Pollack 2003</LINK>), still have to be conducted in treatment-resistant populations. The lack of comorbidity in the patient groups included in this review is not typical of treatment-resistant patients encountered in clinical practice (<LINK REF="REF-Hollander-2002" TYPE="REFERENCE">Hollander 2002</LINK>), further undermining generalisation of this review's findings to all clinical populations. Finally, the inclusion in a number of trials of samples with resistance to different medications limits general conclusions about the efficacy of augmentation of any particular medication. <BR/> <BR/>The quality of evidence upon which the findings of this review are based was relatively poor. Although the low power of the small samples employed by the individual RCTs in this review to detect a treatment effect was partially overcome through meta-analytic procedures, only two trials reported practicing adequate allocation concealment. The failure to mask the identity of patients assigned to the treatment or comparison groups from those involved in the study is the factor that has been most consistently demonstrated as leading to inflated estimates of treatment efficacy (<LINK REF="REF-Als_x002d_Nielsen-2004" TYPE="REFERENCE">Als-Nielsen 2004</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>, but see <LINK REF="REF-Balk-2002" TYPE="REFERENCE">Balk 2002</LINK>). Publication bias may also have contributed to an exaggerated response to treatment, due to a failure to account for smaller negative trials. Finally, the large number of comparisons conducted in this review could have inflated the risk of false positive results (Type I error), despite attempts to limit the number of primary outcomes of interest. Conversely, the failure to detect an effect of clinical or methodological differences between trials on augmentation outcome should not be interpreted as the absence of such an effect, given the limited power of the subgroup analyses to detect these effects. </P>
<P>Putative animal models of OCD, and genetic and brain imaging studies have increasingly implicated the dopaminergic system, providing a rationale for the efficacy of augmentation with antipsychotics in OCD (<LINK REF="REF-Denys-2004c" TYPE="REFERENCE">Denys 2004c</LINK>). An early suggestion was that dopaminergic involvement might be more relevant in OCD patients with tics, and indeed there was evidence of a preferential response in this subgroup to augmentation with the first generation antipsychotic haloperidol (<LINK REF="STD-McDougle-1994" TYPE="STUDY">McDougle 1994</LINK>). However, treatment response in this subgroup of patients was not particularly marked in the trials of the second generation antipsychotics risperidone (<LINK REF="STD-McDougle-2000" TYPE="STUDY">McDougle 2000</LINK>) and quetiapine (<LINK REF="STD-Carey-2005" TYPE="STUDY">Carey 2005</LINK>). Alternative models of the potentiation of the effects of the SSRIs in treating resistant OCD include the inhibition of 5-HT<SUB>2a </SUB>receptors (<LINK REF="REF-Marek-2003" TYPE="REFERENCE">Marek 2003</LINK>). </P>
<P>We were not able to find any long-term maintenance RCTs of medication augmentation in treating resistant anxiety disorders. Open-label evidence of the tolerability of a 12 month augmentation trial of olanzapine in OCD (<LINK REF="REF-Marazziti-2005" TYPE="REFERENCE">Marazziti 2005</LINK>), and high rates of relapse following the discontinuation of additive antipsychotics (<LINK REF="REF-Maina-2003" TYPE="REFERENCE">Maina 2003</LINK>) suggest that long-term medication augmentation might be warranted. The extent to which the efficacy of short-term course of additive antipsychotics in treating resistant OCD can be applied to other anxiety disorders also remains to be determined. <BR/>
<B>
<BR/>
</B>We were unable to determine the minimum effective augmentation dose and duration of treatment for resistant anxiety disorders in the present review. For example, questions regarding the time taken to achieve full treatment response following initiation of additive antipsychotics for resistant OCD remain unresolved, despite widely reported open label evidence for a rapid response to this treatment strategy (<LINK REF="REF-Crocq-2002" TYPE="REFERENCE">Crocq 2002</LINK>, <LINK REF="REF-Francobandiera-2001" TYPE="REFERENCE">Francobandiera 2001</LINK>, <LINK REF="REF-McDougle-1997" TYPE="REFERENCE">McDougle 1997</LINK>, <LINK REF="REF-Saxena-1996" TYPE="REFERENCE">Saxena 1996</LINK>, <LINK REF="REF-Weiss-1999" TYPE="REFERENCE">Weiss 1999</LINK>, but see <LINK REF="REF-Bogetto-2000" TYPE="REFERENCE">Bogetto 2000</LINK>). Response rates following intravenous administration of citalopram in an open label trial of resistant OCD were more rapid than those generally observed when treating patients orally with first-line antidepressants, and suggests the importance of controlled trials comparing the relative efficacy of different routes of administering augmenting medications (<LINK REF="REF-Pallanti-2002b" TYPE="REFERENCE">Pallanti 2002b</LINK>). </P>
<P>A number of open-label findings in this area deserve follow up; this includes work on agents such as D-cycloserine for PTSD (<LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>), amisulpiride (<LINK REF="REF-Metin-2003" TYPE="REFERENCE">Metin 2003</LINK>), N-acetylcysteine (<LINK REF="REF-Lafleur-2006" TYPE="REFERENCE">Lafleur 2006</LINK>) and riluzole (<LINK REF="REF-Coric-2005" TYPE="REFERENCE">Coric 2005</LINK>) for OCD and citalopram (<LINK REF="REF-Simon-2002" TYPE="REFERENCE">Simon 2002</LINK>) for SP. This review was unable to find controlled trials of augmentation medication for anxiety disorders in childhood and adolescence (<LINK REF="REF-Thomsen-2004" TYPE="REFERENCE">Thomsen 2004</LINK>) or geriatric populations. The effectiveness of multimodal augmentation strategies combining psychotherapy and pharmacotherapy must also still be investigated. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Medication augmentation is potentially an effective and well tolerated strategy in combating treatment resistant anxiety disorders. However, most of the evidence for reductions in the severity of symptoms and improved treatment response is restricted to trials of SRI - resistant OCD with antipsychotic medication. Inconsistency between trials in defining treatment response and methodological shortcomings limit the extent to which the findings of this review can be said to be definitive. Treatment effect may also be inflated due to the selective publication of small trials reporting positive results.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The substantial rate of non-response to medication treatment of anxiety disorders underscores the importance of additional controlled clinical trials of medication augmentation. The contribution of these trials towards the evidence base would be facilitated by consensus on the operational definition of treatment resistance, particularly in disorders other than OCD. Questions for future research include the appropriate dose and duration of augmentation medication, precise effects of medication on quality of life measures, and determining factors which predict response to medication (such as baseline severity). Further research on treatment-resistant anxiety disorders in children and adolescents is needed. Additional data are needed to address several areas, including the efficacy of augmentation over the longer-term, and the value of medication augmentation in comparison to other strategies (eg switching medication, adding psychotherapy).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors are supported by the MRC Research Unit on Anxiety and Stress Disorders (Cape Town, South Africa). We wish to thank Eric Hollander (and Nicolo Rossi), Mendel Fux and colleagues, Stefano Pallanti, and Stefano Erzegovesi for responding to requests for additional data for the review. We would also like to express our gratitude to Luzaan van Wyk and Simon Hagger of AstraZeneca and Mark Pollack for letting us have access to unpublished trials, and the CCDAN editorial base for their assistance. Joy Oliver of the South African Cochrane Centre helped retrieve trial reports for inclusion in the review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The MRC Unit on Anxiety Disorders has been supported by each of the pharmaceutical companies with an interest in psychiatry in South Africa.</P>
<P>
<B>Potential conflicts of interest for individual reviewers</B>
</P>
<P>Jonathan Ipser has no known conflicts of interest outside of his affiliation by the MRC Unit on Anxiety Disorders.</P>
<P>Paul Carey has received research grants/honoria from Astra Zeneca, Glaxo-Smithkline, Lundbeck, and Sanofi-Aventis </P>
<P>Yumna Dhansay has no known conflicts of interest outside of her affiliation with the MRC Unit on Anxiety Disorders.</P>
<P>Soraya Seedat has received support from several companies (including GlaxoSmithKline, Eli-Lilly, Pfizer, Cephalon, AstraZeneca, Lundbeck) and has participated in several clinical trials.</P>
<P>Nuraan Fakier has no known conflicts of interest outside of her affiliation with the MRC Unit on Anxiety Disorders.</P>
<P>Dan Stein has received research grants and/or consultancy honoraria from Astrazeneca, Eli-Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, and Wyeth. He has participated in a number of ongoing trials, and has presented data from some of these trials on behalf of the sponsoring companies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Jonathan Ipser was responsible for responding to editorial feedback, for writing the methods and results section of the review and for capturing and analysing the data. Nuraan Fakier assisted in double-checking the trial data captured. Yumna Dhansay completed the background section of the review. Paul Carey and Soraya Seedat provided comprehensive feedback on the review. Dan Stein co-ordinated and provided feedback on the review. Nuraan Fakier assisted in trial retrieval/selection and in double-data entry.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2002" NAME="Atmaca 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E, Gecici O</AU>
<TI>Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>3</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-1997" NAME="Barr 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH</AU>
<TI>Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>9</NO>
<PG>1293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartzokis-2004" NAME="Bartzokis 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS</AU>
<TI>Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>57</VL>
<PG>474-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brawman-2004" NAME="Brawman 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Brawman-Mintzer O, Knapp R, Nietert P</AU>
<TI>Placebo-controlled study of risperidone augmentation in treatment-resistant subjects with DSM-IV diagnosed generalized anxiety disorder</TI>
<SO>conference poster</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bystritsky-2004" NAME="Bystritsky 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM et al</AU>
<TI>Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>565-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carey-2005" NAME="Carey 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ</AU>
<TI>Quetiapine augmentation of SRIs in treatment refractory obsessive compulsive disorder: a double-blind, randomised, placebo-controlled study</TI>
<SO>BMC Psychiatry</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>44</NO>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dannon-2000" NAME="Dannon 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J</AU>
<TI>Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<PG>165-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denys-2004" NAME="Denys 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Denys D, de Geus F, van Megen HJ, Westenberg HG</AU>
<TI>A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>1040-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erzegovesi-2004" NAME="Erzegovesi 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L</AU>
<TI>Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fineberg-2005" NAME="Fineberg 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fineberg NA, Sivakumaran T, Roberts A, Gale T</AU>
<TI>Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fux-1999" NAME="Fux 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fux M, Benjamin J, Belmaker RH</AU>
<TI>Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>193-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamner-2003" NAME="Hamner 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW</AU>
<TI>Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirschmann-2000" NAME="Hirschmann 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L</AU>
<TI>Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>5</NO>
<PG>556-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2003" NAME="Hollander 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Rossi NB, Sood E, Pallanti S</AU>
<TI>Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>397-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koran-2005" NAME="Koran 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliot M</AU>
<TI>Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>3</NO>
<PG>353-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" NAME="Li 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR</AU>
<TI>Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>6</NO>
<PG>736-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1991a" NAME="McDougle 1991a" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR</AU>
<TI>A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>3</NO>
<PG>175-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1991b" NAME="McDougle 1991b" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR</AU>
<TI>A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>3</NO>
<PG>175-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1993" NAME="McDougle 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E et al</AU>
<TI>Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>4</NO>
<PG>647-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-1994" NAME="McDougle 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH</AU>
<TI>Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>4</NO>
<PG>302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDougle-2000" NAME="McDougle 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH</AU>
<TI>A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>4</NO>
<PG>794-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pallanti-1999" NAME="Pallanti 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pallanti S, Quercioli L, Paiva RS, Koran LM</AU>
<TI>Citalopram for treatment-resistant obsessive-compulsive disorder</TI>
<SO>European Psychiatry</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pigott-1991" NAME="Pigott 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pigott TA, Pato MT, L'Heureux F, Hill JL, Grover GN, Bernstein SE et al</AU>
<TI>A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>4</NO>
<PG>242-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollack-2006" NAME="Pollack 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E et al</AU>
<TI>Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>3</NO>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskind-2003" NAME="Raskind 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE et al</AU>
<TI>Reducation of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>2</NO>
<PG>371-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapira-2004" NAME="Shapira 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MCK, Blier P et al</AU>
<TI>A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>5</NO>
<PG>553-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2001" NAME="Stein 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stein MB, Sareen J, Hami S, Chao J</AU>
<TI>Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>10</NO>
<PG>1725-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2002" NAME="Stein 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stein MB, Kline NA, Matloff JL</AU>
<TI>Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>10</NO>
<PG>1777-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Denys-2004b" NAME="Denys 2004b" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Denys D, van Megen HJ, van der Wee N, Westenberg HG</AU>
<TI>A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fallon-1998" NAME="Fallon 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S et al</AU>
<TI>Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<PG>918-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grady-1993" NAME="Grady 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL</AU>
<TI>Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>5</NO>
<PG>819-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-2002" NAME="Heresco-Levy 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M et al</AU>
<TI>Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>301-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mundo-1998" NAME="Mundo 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mundo E, Guglielmo E, Bellodi L</AU>
<TI>Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>5</NO>
<PG>219-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otto-2003" NAME="Otto 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS et al</AU>
<TI>Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>1271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pallanti-2004" NAME="Pallanti 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pallanti S, Quercioli L, Bruscoli M</AU>
<TI>Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: A pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1394-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pigott-1992" NAME="Pigott 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL</AU>
<TI>A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pollack-2003" NAME="Pollack 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F et al</AU>
<TI>Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>3</NO>
<PG>276-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Fux-2004" NAME="Fux 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fux M,Benjamin J, Nemets B</AU>
<TI>A placebo-controlled cross-over trial of adjunctive EPA in OCD</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>3</NO>
<PG>323-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskind-2006" NAME="Raskind 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Raskind M</AU>
<TI>Prazosin for Noncombat Trauma PTSD</TI>
<SO>CRISP (http://crisp.cit.nih.gov/)</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NIH Grant No: 1R01MH069867-01A2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Simon-2006" NAME="Simon 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Simon NM</AU>
<TI>Treatment refractory panic disorder</TI>
<SO>CRISP (http://crisp.cit.nih.gov/)</SO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NIH Grant No: 5K23MH001831-05"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Ackerman-2002" NAME="Ackerman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman DL, Greenland S</AU>
<TI>Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>309-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2003" NAME="Alderson 2003" TYPE="BOOK_SECTION">
<AU>Alderson P, Green S, Higgins JP</AU>
<TI>Assessment of study quality</TI>
<SO>Cochrane Reviewers&#8217; Handbook 4.2.1 [updated December] Section 8;</SO>
<YR>2004</YR>
<NO>1</NO>
<ED>Alderson P, Green S, Higgins JPT</ED>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2003" NAME="Als-Nielsen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen B, Chen W, Gluud C, Kjaergard LL</AU>
<TI>Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>921-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2004" NAME="Als-Nielsen 2004" TYPE="CONFERENCE_PROC">
<AU>Als-Nielsen B, Chen W, Gluud LL, Siersma V, Hilden J, Gluud C</AU>
<TI>Are trial size and reported methodological quality associated with treatment effects? Observational study of 523 randomised trials</TI>
<SO>12th Cochrane Colloquium: Bridging the Gaps; 2004 Oct 2-6; Ottawa, Ontario, Canada</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arias-2002" NAME="Arias 2002" TYPE="OTHER">
<AU>Arias F, Soto JA, Garcia MJ, Rodriguez-Calvin JL, Morales J, Salgado M</AU>
<TI>Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive compulsive disorder [Abstract]</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12 Suppl 3</VL>
<PG>S341</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baker-2003" NAME="Baker 2003" TYPE="JOURNAL_ARTICLE">
<AU>Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW</AU>
<TI>Quantitative analysis of sponsorship bias in economic studies of antidepressants</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>183</VL>
<PG>498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bakker-2002" NAME="Bakker 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bakker A, van Balkom AJ, Spinhoven P</AU>
<TI>SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>3</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balk-2002" NAME="Balk 2002" TYPE="JOURNAL_ARTICLE">
<AU>Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C et al</AU>
<TI>Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>22</NO>
<PG>2973-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bandelow-2002" NAME="Bandelow 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ</AU>
<TI>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>4</NO>
<PG>171-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bandelow-2004" NAME="Bandelow 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bandelow B, Ruther E</AU>
<TI>Treatment-resistant panic disorder</TI>
<SO>CNS Spectrums</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>10</NO>
<PG>725-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BAP-2005" NAME="BAP 2005" TYPE="JOURNAL_ARTICLE">
<AU>Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR et al</AU>
<TI>Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>6</NO>
<PG>567-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1999" NAME="Berlin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA, Rennie D</AU>
<TI>Measuring the quality of trials: The quality of quality scales</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1083-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blake-1990" NAME="Blake 1990" TYPE="JOURNAL_ARTICLE">
<AU>Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD. Charney DS et al</AU>
<TI>The development of a Clinician-Administered PTSD Scale</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>1</NO>
<PG>75-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blanco-2003" NAME="Blanco 2003" TYPE="JOURNAL_ARTICLE">
<AU>Blanco C, Schneier FR, Schmidt A, Blanco-Jerez C, Marshall RD, Sanchez-Lacay A et al</AU>
<TI>Pharmalogical treatment of social anxiety disorder: A meta-analysis</TI>
<SO>Depression and Anxiety</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>29-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bogan-2005" NAME="Bogan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A</AU>
<TI>Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>1</NO>
<PG>73-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bogetto-2000" NAME="Bogetto 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bogetto F, Bellino S, Vaschetto P, Ziero S</AU>
<TI>Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial</TI>
<SO>Psychiatry Research</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>2</NO>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyer-1995" NAME="Boyer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Boyer M</AU>
<TI>Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Butler-2005" NAME="Butler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Butler AC, Chapman JE, Forman EM, Beck AT</AU>
<TI>The empirical status of cognitive-behavioral therapy: A review of meta-analyses</TI>
<SO>Clinical Psychology Review</SO>
<YR>2006</YR>
<VL>1</VL>
<PG>17-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coric-2005" NAME="Coric 2005" TYPE="JOURNAL_ARTICLE">
<AU>Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G et al</AU>
<TI>Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>5</NO>
<PG>424-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cowley-1997" NAME="Cowley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cowley DS, Ha EH, Roy-Byrne PP</AU>
<TI>Determinants of pharmacologic treatment failure in panic disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>12</NO>
<PG>555-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crocq-2002" NAME="Crocq 2002" TYPE="JOURNAL_ARTICLE">
<AU>Crocq MA, Leclercq P, Guillon MS, Bailey PE</AU>
<TI>Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment</TI>
<SO>European Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>296-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2003" NAME="D'Amico 2003" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R et al</AU>
<TI>Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder</TI>
<SO>Progress in Neuro-psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>4</NO>
<PG>619-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ.</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey SG, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2002" NAME="Deeks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ</AU>
<TI>Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1575-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2005" NAME="Deeks 2005" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Cochrane Reviewers&#8217; Handbook 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<ED>Alderson P, Green S, Higgins J</ED>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denys-2002" NAME="Denys 2002" TYPE="JOURNAL_ARTICLE">
<AU>Denys D, van Megen H, Westenberg H</AU>
<TI>Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>8</NO>
<PG>700-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denys-2004c" NAME="Denys 2004c" TYPE="JOURNAL_ARTICLE">
<AU>Denys D, Zohar J, Westenberg HG</AU>
<TI>The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65 Suppl 14</VL>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eddy-2004" NAME="Eddy 2004" TYPE="JOURNAL_ARTICLE">
<AU>Eddy KT, Dutra L, Bradley R, Westen D</AU>
<TI>A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder</TI>
<SO>Clinical Psychology Review</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>1011-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne ER, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: Methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fedoroff-2001" NAME="Fedoroff 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fedoroff IC, Taylor S</AU>
<TI>Psychological and pharmacological treatments of social phobia: a meta-analysis</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>3</NO>
<PG>311-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Francobandiera-2001" NAME="Francobandiera 2001" TYPE="JOURNAL_ARTICLE">
<AU>Francobandiera G</AU>
<TI>Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>4</NO>
<PG>356-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1989" NAME="Goodman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al</AU>
<TI>The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>11</NO>
<PG>1006-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-1999" NAME="Greenberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR et al</AU>
<TI>The economic burden of anxiety disorders in the 1990s</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>7</NO>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>U.S. National Institute of Health</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heimberg-1998" NAME="Heimberg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA et al.</AU>
<TI>Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>12</NO>
<PG>1133-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JTP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>6</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollander-2002" NAME="Hollander 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA et al</AU>
<TI>Refractory Obsessive-Compulsive Disorder: State-of-the-Art treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63 Suppl 6</VL>
<PG>20-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2000" NAME="Hunter 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hunter JE, Schmidt FL</AU>
<TI>Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge</TI>
<SO>International Journal of Selection and Assessment</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>4</NO>
<PG>275-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobsen-1995" NAME="Jacobsen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen FM</AU>
<TI>Risperidone in the treatment of affective illness and obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>9</NO>
<PG>423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karno-1988" NAME="Karno 1988" TYPE="JOURNAL_ARTICLE">
<AU>Karno M, olding JM, Sorenson SB, Burnam MA</AU>
<TI>The epidemiology of obsessive-compulsive disorder in five US communities</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>12</NO>
<PG>1094-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1994" NAME="Kessler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al</AU>
<TI>Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>1</NO>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-2005" NAME="Kessler 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE</AU>
<TI>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>6</NO>
<PG>593-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koran-2000" NAME="Koran 2000" TYPE="JOURNAL_ARTICLE">
<AU>Koran LM, Ringold AL, Elliott MA</AU>
<TI>Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>7</NO>
<PG>514-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lafleur-2006" NAME="Lafleur 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G et al</AU>
<TI>N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>2</NO>
<PG>254-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Law-2003" NAME="Law 2003" TYPE="COCHRANE_REVIEW">
<AU>Law J, Garrett Z, Nye C</AU>
<TI>Speech and language therapy interventions for children with primary speech and language delay or disorder</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>Wiley</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lecrubier-1997" NAME="Lecrubier 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lecrubier Y, Sheehan D, Weiller E, Amorim P. Bonora I. Sheehan KH et al.</AU>
<TI>The Mini-International Neuropsychiatric Interview (MINI) a short diagnostic structured interview: reliability and validity according to the CIDI</TI>
<SO>European Psychiatry</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>5</NO>
<PG>224-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebowitz-1987" NAME="Liebowitz 1987" TYPE="JOURNAL_ARTICLE">
<AU>Liebowitz MR</AU>
<TI>Social Phobia</TI>
<SO>Modern Problems of Pharmacopsychiatry.</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>141-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundbeck-2003" NAME="Lundbeck 2003" TYPE="OTHER">
<AU>Lundbeck</AU>
<TI>Psychotropics</TI>
<SO>http://www.psychotropics.dk/about.asp</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maina-2003" NAME="Maina 2003" TYPE="JOURNAL_ARTICLE">
<AU>Maina G, Albert U, Ziero S, Bogetto F</AU>
<TI>Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marazziti-2005" NAME="Marazziti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Marazziti D, Pfanner C, Dell'Osso B, Ciapparelli A, Presta S, Corretti G et al</AU>
<TI>Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>4</NO>
<PG>392-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marek-2003" NAME="Marek 2003" TYPE="JOURNAL_ARTICLE">
<AU>Marek GJ, Carpenter LL, McDougle CJ, Price LH</AU>
<TI>Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>2</NO>
<PG>402-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDougle-1997" NAME="McDougle 1997" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH</AU>
<TI>Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>11</NO>
<PG>526-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendlowicz--2000" NAME="Mendlowicz  2000" TYPE="JOURNAL_ARTICLE">
<AU>Mendlowicz MV, Stein MB</AU>
<TI>Quality of life in individuals with anxiety disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>5</NO>
<PG>669-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metin-2003" NAME="Metin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Metin O, Yazici K, Tot S, Yazici AE</AU>
<TI>Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial</TI>
<SO>Human Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>463-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Misri-2004" NAME="Misri 2004" TYPE="JOURNAL_ARTICLE">
<AU>Misri S, Milis L</AU>
<TI>Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>624-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitte-2005" NAME="Mitte 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mitte K, Noack P, Steil R, Hautzinger M</AU>
<TI>A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder.</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>2</NO>
<PG>141-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitte-2005b" NAME="Mitte 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Mitte K</AU>
<TI>A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2005</YR>
<VL>88</VL>
<NO>1</NO>
<PG>27-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitte-2005c" NAME="Mitte 2005c" TYPE="JOURNAL_ARTICLE">
<AU>Mitte K</AU>
<TI>Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy</TI>
<SO>Psychological Bulletin</SO>
<YR>2005</YR>
<VL>131</VL>
<NO>5</NO>
<PG>785-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-2001" NAME="Moncrieff 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moncrieff J, Churchill R, Drummond DC, McGuire H</AU>
<TI>Development of a quality assessment instrument for trials of treatments for depression and neurosis</TI>
<SO>International Journal of Methods in Psychiatric Research</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>3</NO>
<PG>126-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1994" NAME="Murray 1994" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopez AD, Jamison DT</AU>
<TI>The global burden of disease in 1990: summary results, sensitivity analysis and future directions</TI>
<SO>Bulletin of the World Health Organisation</SO>
<YR>1994</YR>
<VL>72</VL>
<PG>495-509</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pallanti-2002" NAME="Pallanti 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D et al</AU>
<TI>Treatment non-response in OCD: methodological and operational definitions</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pallanti-2002b" NAME="Pallanti 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Pallanti S, Quercioli L, Koran LM</AU>
<TI>Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>9</NO>
<PG>796-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pfanner-2000" NAME="Pfanner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A et al</AU>
<TI>Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>297-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Power-1990" NAME="Power 1990" TYPE="JOURNAL_ARTICLE">
<AU>Power KG, Simpson RJ, Swanson V, Wallace LA.</AU>
<TI>Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care</TI>
<SO>British Journal of General Practice</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>336</NO>
<PG>289-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R-2005" NAME="R 2005" TYPE="COMPUTER_PROGRAM">
<AU>R Development Core Team</AU>
<TI>R: A Language and Environment for Statistical Computing</TI>
<YR>2005</YR>
<PB>R Foundation for Statistical Computing</PB>
<CY>Vienna</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISBN 3-900051-07-0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ravizza-1996" NAME="Ravizza 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G</AU>
<TI>Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD)</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>4</NO>
<PG>677-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saxena-1996" NAME="Saxena 1996" TYPE="JOURNAL_ARTICLE">
<AU>Saxena S, Wang D, Bystritsky A, Baxter LR Jr</AU>
<TI>Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>7</NO>
<PG>303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shear-1997" NAME="Shear 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW et al</AU>
<TI>Multicenter collaborative panic disorder severity scale</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>11</NO>
<PG>1571-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheehan-1996" NAME="Sheehan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan DV, Harnett-Sheehan K, Raj BA</AU>
<TI>The measurement of disability</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11 Suppl 3</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2002" NAME="Simon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Simon NM, Korbly NB, Worthington JJ, Kinrys G, Pollack MH</AU>
<TI>Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients</TI>
<SO>CNS Spectrums</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>9</NO>
<PG>655-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-1995" NAME="Stein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stein DJ, Spadaccini E, Hollander E</AU>
<TI>Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-2006" NAME="Stein 2006" TYPE="COCHRANE_REVIEW">
<AU>Stein DJ, Ipser JC, Seedat S</AU>
<TI>Pharmacotherapt for posttraumatic stress disorder.</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1:CD002795.pub2</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Bognor Regis</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomsen-2004" NAME="Thomsen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thomsen PH</AU>
<TI>Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>4</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verbeek--2000" NAME="Verbeek  2000" TYPE="BOOK">
<AU>Verbeke M, Molenberghs G</AU>
<SO>Linear mixed models for longitudinal data</SO>
<YR>2000</YR>
<PB>Springer</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" NAME="Ware 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE Jr, Sherbourne CD</AU>
<TI>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</TI>
<SO>Medical Care</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>6</NO>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1999" NAME="Weiss 1999" TYPE="JOURNAL_ARTICLE">
<AU>Weiss EL, Potenza MN, McDougle CJ, Epperson CN</AU>
<TI>Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>8</NO>
<PG>524-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WFSBP-2002" NAME="WFSBP 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ</AU>
<TI>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>4</NO>
<PG>171-99</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Atmaca-2002">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, single-blind trial</P>
<P>BLINDING<BR/>Participants: Unclear (probably)<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 27 DSM-IV OCD, resistant to 12 weeks of clomipramine, fluoxetine, fluvoxamine (in combination with clonazepam, alprazolam, pimozide, or lithium in 6 patients), 8 (29.6%) MDD, 14 (52%) female, average age: 28.3 (18-49), average duration of illness: 6.7 years, baseline severity on Y-BOCS: 24.1 (quetiapine), 23.8 (placebo)</P>
<P>SCREENING<BR/>Primary diagnosis: None<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: quetiapine 50 mg/d - 200 mg/d (mean dose: 91.1 mg/d) versus placebo x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, CGI-I (no distinction was made between primary and secondary outcomes)</P>
<P>Data estimation: OC (no withdrawals)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 0<BR/>Quality rating score: 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Barr-1997">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 33 DSM-III-R OCD, resistant to &gt;= 10 weeks of fluvoxamine, fluoxetine and sertraline, average age of 6 wk completers: 37.9 years, 57% (17/30) female, MDD present</P>
<P>SCREENING<BR/>Primary diagnosis: min dose for 4 weeks of 250mg/d fluovoxamine, 80mg/d fluoxetine, 200mg/d sertraline; YBOCS &gt;= 16, CGI-I = 3+ <BR/>Comorbidity: Unclear<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: desipramine (mean final dose: 150.9mg/d) versus placebo x 6 weeks, followed by 4 week extension for subgroup</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>YBOCS, HAM-D (25-item), BDI (no distinction between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes<BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: No information provided<BR/>Quality rating score: 17<BR/>Low-dose stabilised course of benzodiazepines permitted and behaviour therapy continued, if it did not improve patients condition in prior month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bartzokis-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 65 DSM-IV PTSD, 100% male, mean age: 51.6 years (38-63), baseline severity on CAPS: 102.2 on risperidone and 98.6 on placebo</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS &lt;= 65<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 1mg/d - 3mg/d versus placebo x 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS <BR/>Secondary outcomes: HAM-A, HAM-D, PANSS-P, BAS, CS (abbrev.), AIMS</P>
<P>Data estimation: Mixed model multiple regression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 33% (11/33) on risperidone and 18.8% (6/32) on placebo<BR/>Quality rating score: 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brawman-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 40 DSM-IV GAD, unresponsive to prior anxiolytic for &gt;= 4 weeks, average age of LOCF sample: 37.9 years, 85% (33/39) female, no participants with MDD, duration of diagnosis: 21.1 years, baseline severity on HAM-A: risperidone (22.1) and placebo (20.4)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID, HAM-A &gt; 18 - item 1 &amp; 2 &gt; 2, CAS total &gt; RDS scores<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 0.5mg/d - 1.5mg/d (mean: 1.1mg/d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A, CGI-S, CGI-S, MADRS, HAD, SDS, AIMS (no distinction was made between primary and secondary outcomes)</P>
<P>Data estimation: LOCF (excluding participants with less than 1 dosage and post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 21% (4/19) on risperidone and 20%(4/20) on placebo<BR/>Quality rating score: 23<BR/>Agent which was augmented was not necessarily the anxiolytic to which resistance was determined</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bystritsky-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: balanced randomisation procedure employed by pharmacist</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 26 DSM-IV OCD, unresponsive to at least 12 weeks of fluoxetine (mean dose: 60 mg/d), paroxetine (mean dose: 80 mg/d), sertraline (200 mg/d) or clomipramine (mean dose: 225 mg/d), average age: 41.4 years, 50% male, baseline severity on Y-BOCS: olanzepine (24.2), placebo (25.2)</P>
<P>SCREENING<BR/>Primary diagnosis: MINI, HAM-D &lt;=21<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: olanzapine 2.5 mg/d &#8211; 20 mg/d (mean final dose: 11.2 mg/d) versus placebo (mean final dose: 16.9 mg/d)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>YBOCS, HAM-D, HAM-A, CGI (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear<BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 2 on olanzapine and 6 on placebo<BR/>Quality rating score: 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Carey-2005">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: pharmaceutical company packaged medication in numbered dispensing wallets</P>
<P>RANDOMISATION<BR/>Method: computer generated randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 42 DSM-IV OCD, unresponsive to at least 12 weeks of fluoxetine (median dose: 60 mg/d), citalopram (median dose: 60 mg/d), paroxetine (median dose: 60 mg/d), fluvoxamine (median dose: 300 mg/d), sertraline (median dose: 200 mg/d) or clomipramine (median dose: 250 mg/d), average age of LOCF sample: 32.8 years, 53.7% (22/41) male, baseline severity on Y-BOCS: quetiapine (26.4), placebo (27.7)</P>
<P>SCREENING<BR/>Primary diagnosis: MINI<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: quetiapine 25mg/d &#8211; 300mg/d (mean final dose: 168.75mg/d) versus placebo (mean final dose:228.57mg/d) x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: Y-BOCS, CGI-I<BR/>Secondary outcomes: CGI-S, MADRS, SDS, YGTSS</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates due to adverse effects: 2 on quetiapine and 0 on placebo<BR/>Quality rating score: 28<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dannon-2000">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised fixed dose placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-IV OCD, unresponsive to at least 15 weeks of paroxetine (up to 60 mg/d), 57.1% (8/14) male, average age of OC sample: 33.8 years, average duration of illness for OC sample: 0.6 year, baseline severity for OC sample on Y-BOCS: pindolol (28.8), placebo (31.2)</P>
<P>SCREENING<BR/>Primary diagnosis: Y-BOCS<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: pindolol 2.5mg t.i.d. versus placebo x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, MADRS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 0 on pindolol, 2 on placebo<BR/>Quality rating score: 18</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Denys-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised flexible dose placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 40 DSM-IV OCD, unresponsive to at least 8 weeks of venlafaxine, paroxetine, fluoxetine, citalopram, imipramine or clomipramine, 75% female, average age: 35.2 years, average duration of illness: 21.4 years, baseline severity on Y-BOCS: quetiapine (28.2), placebo (26.4)</P>
<P>SCREENING<BR/>Primary diagnosis: MINI, Y-BOCS &gt;=18 or Y-BOCs &gt;=12 if only obsessions or compulsions present <BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: quetiapine 50mg/d &#8211; 300mg/d versus placebo x 8 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: Y-BOCS, CGI-I<BR/>Secondary outcomes: HAM-A, HAM-D, BABS, SDS</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1 on quetiapine and 0 on placebo<BR/>Quality rating score: 29</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Erzegovesi-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised fixed dose placebo-controlled trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: randomised list kept in software protected spreadsheet</P>
<P>RANDOMISATION<BR/>Method: computer generated randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 39 DSM-IV OCD, 20 unresponsive to 12 weeks open-label fluvoxamine treatment (50 mg/d - 300 mg/d), average age: 34.9 years, average duration of illness: 13.6 years, baseline severity on Y-BOCS: risperidone (30.9), placebo (26,4)</P>
<P>SCREENING<BR/>Primary diagnosis: DIS-R<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 0.5mg/die versus placebo x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, NIMH-OC, HAM-D, CGI (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: Unclear<BR/>Quality rating score:</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fineberg-2005">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised flexible dose placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 21 DSM-IV OCD, no comorbid tics, 57% female, average age: 37.6 years, baseline severity on Y-BOCS: 24.5 (quetiapine), 24.1 (placebo)</P>
<P>SCREENING<BR/>Primary diagnosis: None<BR/>Comorbidity: MADRS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: quetiapine 25 mg/d - 400 mg/d (mean dose at endpoint: 215 mg/d) versus placebo x 16 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS (10 item), YGTSS, NIMH-GOCS, CGI-S, CGI-I, MADRS, SDS, SAS, BAS, AIMS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1 on quetiapine, 1 on placebo<BR/>Quality rating score: 25</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fux-1999">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, crossover, fixed dose, randomised placebo-controlled trial, without washout</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 13 DSM-IV OCD, unresponsive to 8 weeks of treatment with fluoxetine (40 - 60 mg), fluvoxamine (200-250 mg), chlorimipramine (150 - 225 mg), 80% of OC sample female, average age of OC sample: 30.3 years, average duration of illness of OC sample: 11.1 years, baseline severity for OC sample on on Y-BOCS: 27.6</P>
<P>SCREENING<BR/>Primary diagnosis: Clinical interview<BR/>Comorbidity: Unclear<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: inositol 6 mg/d versus placebo x 12 weeks (6 weeks for both phases)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, HAM-A (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 3<BR/>Quality rating score: 16<BR/>Patients described as not responding adequately to SRI therapy, although no scale used to determine whether sample was treatment resistant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamner-2003">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial, 1 week single-blind placebo run-in </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 40 DSM-IV chronic PTSD, war veterans, described as "somewhat treatment refractory" to SSRIs, benzodiazepines, lithium, carbamazepine, 100% (37/37) of LOCF sample male, average age of LOCF sample: 52 years, 86.5% (32/37) with depression according to HAM-D, baseline severity on CAPS for LOCF sample: risperidone (90.3) and placebo (89.1)</P>
<P>
<BR/>SCREENING<BR/>Primary diagnosis: SCID-P, PANSS &gt;= 60<BR/>Comorbidity: HAM-D</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 1 mg/d - 6 mg/d (mean dose: 2.5 mg/d) versus placebo x 5 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: PANSS<BR/>Secondary outcomes: CAPS, BAS, AIMS, SAS</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 9 on risperidone, 6 on placebo<BR/>Quality rating score: 25<BR/>Patients with &gt; 20% decline on PANSS during placebo lead-in excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hirschmann-2000">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised fixed dose placebo-controlled trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 26 DSM-III-R Panic Disorder, unresponsive to 8 weeks treatment with oral fluoxetine (20 mg/d), 52% (13/25) female, 1 participants with MDD, average age of OC sample: 41.8 years, baseline severity on CAS+PA: pindolol (15.9), placebo (17.9)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: pindolol 7.5mg/d versus placebo x 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAS+PA, PSQ, HAM-D, HAM-A, NIMH-AS, CGI (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC (assumed)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1 participant (no information on group membership)<BR/>Quality rating score: 22</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hollander-2003">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes (for drug assignment, not side-effects_)<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-IV OCD, unresponsive to concurrent SRI medication for &gt;= 12 weeks (minimum dosage of 200mg/d clomipramine, 60mg/d fluoxetine, 150mg/d fluvoxamine, 150 mg/d sertraline, 60mg/d citalopram and 325mg/d venlafaxine), average age: 39.2 years, 56% (9/16) male, duration of diagnosis: 21.8 years, baseline severity on Y-BOCS: risperidone (29.2) and placebo (29.33). </P>
<P>
<BR/>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 0.5 mg/d - 3 mg/d (mean: 2.25 mg/d) and placebo 0.5 mg/d (2.75 mg/d) x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CGI-I, CGI-S, Y-BOCS, HAM-D (no distinction was made between primary and secondary outcomes)</P>
<P>Data estimation: ITT with LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1/10 for medication, 2/6 for placebo group<BR/>Quality rating score: 31<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Koran-2005">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, crossover, 3 phase, randomised placebo-controlled trial, no washout period </P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 23 DSM-IV OCD, unresponsive to 2 or more SRI trials of at least 8 weeks, 73.9% male, average age: 40 years, baseline severity on Y-BOCS: 28.4 years</P>
<P>SCREENING<BR/>Primary diagnosis: MINI<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: morphine 30 mg/d - 45 mg/d versus lorazepam 1 mg/d - 2 mg/d versus placebo x 6 weeks (2 weeks each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, MADRS (no distinction between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear<BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1 on morphine, 0 on lorazepam and placebo<BR/>Quality rating score: 23</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2005">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, placebo-controlled, randomised, fixed dose crossover trial, 1 week single-blind placebo run-in, 1 week washout period between phases </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-IV OCD, unresponsive to at least 12 weeks of fluoxetine or paroxetine (both at doses of at least 40 mg/d), or fluvoxamine (&gt;= 200 mg/d), or sertraline (&gt;= 100 mg/d), no MDD, average age: 33.6 years, age range: 19-56 years, average duration of OCD symptoms: 9 years, baseline severity on Y-BOCS: 24.33</P>
<P>SCREENING<BR/>Primary diagnosis: SADS-L<BR/>Comorbidity: SADS-L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone (1 mg/d) versus haloperidol (2 mg/d) versus placebo x 9 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D (17item), SCL-90R,POMS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: MM with completer data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 4<BR/>Quality rating score: 21</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDougle-1991a">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 30 DSM-III-R OCD, unresponsive to minimum 8 weeks fluoxetine treatment, 63% (19/30) female, average age: 35.2 years, 46.7% MDD, baseline severity on Y-BOCS: lithium (26.5), placebo (25) </P>
<P>SCREENING<BR/>Primary diagnosis: Unclear <BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: lithium 900 mg/d - 954.5 mg/d (0.5-1.2 mmol/litre serum) versus placebo x 2 weeks for one sample, and lithium versus placebo x 4 weeks for another</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, HAM-A, CGI-I, PGIS (no distinction made between primary and secondary outcomes)</P>
<P>
<BR/>Data estimation:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Yes<BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: No dropouts reported<BR/>Quality rating score: 27<BR/>Low-dose benzodiazepines provided to facilitate sleeping</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDougle-1991b">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 30 DSM-III-R OCD, unresponsive to minimum 8 weeks fluoxetine treatment, 63% (19/30) female, average age: 35.2 years, 46.7% MDD, baseline severity on Y-BOCS: lithium (26.5), placebo (25) </P>
<P>SCREENING<BR/>Primary diagnosis: Unclear <BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: lithium 900 mg/d - 954.5 mg/d (0.5-1.2 mmol/litre serum) versus placebo x 2 weeks for one sample, and lithium versus placebo x 4 weeks for another</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, HAM-A, CGI-I, PGIS (no distinction made between primary and secondary outcomes)</P>
<P>
<BR/>Data estimation:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>NDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Yes<BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: No dropouts reported<BR/>Quality rating score: 27<BR/>Low-dose benzodiazepines provided to facilitate sleeping</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDougle-1993">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, flexible dose, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 33 DSM-III-R OCD, unresponsive to 8 week fluvoxamine trial, 51.5% female, average age: 34.2 years, baseline severity on Y-BOCS: buspirone (26.2), placebo (23.1)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: buspirone 15 mg/d - 60 mg/d (mean dose: 59.2 mg/d) versus placebo (mean dose: 60 mg/d) x 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, HAM-A, CGI-I (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC (no withdrawals reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: Unclear </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: None reported<BR/>Quality rating score: 22<BR/>Low-dose benzodiazepines provided for sleeping</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDougle-1994">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, flexible dose, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 34 DSM-III-R OCD, 15 with comorbid tic disorder or Tourette's syndrome, unresponsive to 8 weeks of fluvoxamine treatment, 26.5% (9/34) unreponsive to 2 previous SRIs, 76.5% female, average age: 34.9 years, baseline severity on Y-BOCS: haloperidol (25.4), placebo (24.9)</P>
<P>SCREENING<BR/>Primary diagnosis: Interview modelled after the SADS<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: haloperidol 2 mg/d - 10 mg/d (mean: 6.2 mg/d) versus placebo (mean: 7.4 mg/d) x 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D, HAM-A, CGI-I, YGTSS, PRAS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC (no withdrawals reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: None reported<BR/>Quality rating score: 26<BR/>Patients given benztropine mesylate (1 mg/d) as prophylaxis against extrapyramidal symptoms. 29% of haloperidol-treated patients required adjunctive propranol in addition to prophylactic benztropine for akathisia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McDougle-2000">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, flexible dose, randomised placebo-controlled trial </P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Computer-generated list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 36 DSM-IV OCD, 12 with comorbid tic disorders (Tourette's and chronic motor tic disorders), unresponsive to 12 weeks open-label SRI (clomipramine, fluoxetine, fluvoxamine, sertraline, paroxetine) treatment, treated with average of 3.6 prior agents, 58.3% male, average age: 31 years, 30 MDD (see Notes section), baseline severity on Y-BOCS: risperidone (27.4), placebo (27.6)</P>
<P>SCREENING<BR/>Primary diagnosis: Interview modelled after the SADS<BR/>Comorbidity: STSOBS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone 1 mg/d - 6 mg/d (mean dose: 2.2 mg/d) versus placebo (mean dose: 2.6 mg/d) x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D (19 item), HAM-A, CGI-I, YGTSS, PRAS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 2 on risperidone and 1 on placebo<BR/>Quality rating score: 29<BR/>Depression defined as DSM-IV diagnosis and score of greater than 20 on the HAM-D, 7 patients received no medication prior to concurrent SRI trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pallanti-1999">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: open-label, parallel, fixed dose, randomised, no-treatment controlled trial , following 4 week washout period</P>
<P>BLINDING<BR/>Participants: No<BR/>Assessors: No<BR/>Administrators: No </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: None</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-II-R OCD, including tic disorders, unresponsive to 2 separate trials of fluoxetine (mean dose: 53.1 mg/d) and clomipramine (mean dose: 173.4 mg/d) of at least 12 weeks, 62.5% male, average age: 26.5 years, baseline severity on Y-BOCS: clomipramine (34.4 mg/d), no treatment (32 mg/d) </P>
<P>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: SCID-II, YGTSS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: clomipramine 25 mg/d - 150 mg/d plus citalopram 20 mg/d - 40 mg/d versus citalopram 20 mg/d - 40 mg/d x 12 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, HAM-D (19 item), YGTSS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 0 reported<BR/>Quality rating score: 23<BR/>Dosage regime for citalopram in augmentation group not identical to no-treatment group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pigott-1991">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, crossover, flexible dose, randomised placebo-controlled trial, without washout</P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: medication placed in identical capsules by central agency</P>
<P>RANDOMISATION<BR/>Method: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-III-R OCD, unresponsive to 6 months stable dosage of clomipramine, 50% male, average age: 39 years, duration of illness: 19 years, baseline severity on Y-BOCS: 17</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: Triiodothyronin 25 ug/d versus lithium carbonate 300 mg/d - 1500 mg/d x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS, NIMH-OC, HAM-D (24 item) (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: OC (ITT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Unclear</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 0<BR/>Quality rating score: 22 <BR/>Sample restricted to partial responders. Placebo capsules merely used to maintain blind between lithium and thyroid medication groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pollack-2006">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Double-blind, randomised, placebo-controlled, parallel, flexible dose study</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 24 DSM-IV GAD, unresponsive to 6 weeks of fluoxetine (end dose: 20 mg/d), 62% (13/21) female, 23% (5/21) MDD, average age of LOCF sample: 43.8 years, average duration of illness of LOCF sample: 24.9 years, baseline severity on HAM-A: olanzapine (17.4), placebo (22.6) </P>
<P>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: olanzapine 2.5 mg/d - 20 mg/d (average endpoint dose: 8.7 mg/d) versus placebo x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: HAM-A, CGI-S <BR/>Secondary outcomes: HAM-D, ASI, SAESS, BAS</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 5 (41.7%) on olanzapine and 2 (16.7%) on placebo<BR/>Quality rating score: <BR/>Three patients remained on concurrent, stable doses of benzodiazepines (one on diazepam and two on alprazolam) during open-label fluoxetine phase -- not clear whether these participants continued into augmentation phase</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Raskind-2003">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, cross-over, flexible dose, randomised placebo-controlled trial, 2 week washout</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 10 DSM-IV chronic PTSD, war veterans, 100% male, average age: 53 years, baseline severity on CAPS: prazosin (79.1), placebo (83.6)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: prazosin 1 mg/d - 10 mg/d versus placebo x 20 weeks (9 weeks of each phase)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS (2 items), CGI-I<BR/>Secondary outcomes: CAPS total score + subscales</P>
<P>Data estimation: LOCF (ITT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 4 in 2nd phase of placebo<BR/>Quality rating score: 20<BR/>Participants considered treatment resistant due to nature of trauma (war veterans)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shapira-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, flexible dose, randomised placebo-controlled trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 44 DSM-IV OCD, 23 partial (CGI-S &gt;= moderate and Y-BOCS &gt;= 16) and 21 nonresponders (Y-BOCS &lt; 25%) to 8 weeks of up to 40 mg/d open-label fluoxetine, 9 patients with tics, 43 adults and 1 adolescent, 59.1% female, average age: 36.9 years, baseline severity on Y-BOCS not provided</P>
<P>SCREENING<BR/>Primary diagnosis: CGI-S, Y-BOCS<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: olanzapine 5 mg/d - 10 mg/d versus placebo x 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Y-BOCS (no distinction was made between primary and secondary outcomes)</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 5 on olanzapine and 2 on placebo<BR/>Quality rating score: 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stein-2001">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, fixed dose, randomised placebo-controlled trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 19 DSM-IV SP, unresponsive (CGI-I &gt; 1) to a minimum of 10 weeks of treatment with paroxetine (average dose before augmentation: 46.4 mg/d), average age and baseline severity not provided</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: pindolol 5 mg/d versus placebo x 4 weeks each phase, each phase followed by 2 week taper period<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>LSAS, CGI-I, SPI (no distinction was made between primary and secondary outcomes)</P>
<P>Data estimation: OC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 5 across both phases<BR/>Quality rating score: 18</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stein-2002">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: double-blind, parallel, flexible dose, randomised placebo-controlled trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 21 DSM-IV chronic PTSD, war veterans, unresponsive to at least 12 weeks of treatment with fluoxetine (median dose: 40 mg/d), paroxetine (median dose: 40 mg/d) or sertraline (median dose: 200 mg/d), 100% male, average age of LOCF sample: 53.3 years, baseline severity on CAPS: olanzapine (86.1), placebo (84)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: olanzapine 10 mg/d - 20 mg/d (mean dose: 15 mg/d) versus placebo (mean dose: 20 mg/d) x 8 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS, CES-D, PSQI, CGI-I (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: LOCF (except for 2 patients lost to follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 3 on olanzapine and 2 on placebo (not including 2 LTF patients) <BR/>Quality rating score: 18<BR/>It is not specified in article what criteria were employed in determining whether patients were nonresponders</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Acronyms for scales: AIMS: Abnormal Involuntary Movement Scale; BAS: Barnes Akathasia Scale; BDI: Beck Depression Inventory; CAS+PA: Clinical Anxiety Scale with Panic Attacks; CES-D: Center for Epidemiological Studies Depression Scale; DIS-R: Diagnostic Interview Schedule - Revised; GAF: Global Assessment of Functioning scale; HAM-D: Hamilton Depression Scale; LSAS: Liebowitz Social Anxiety Scale; MADRS: Montgomery-Asberg Depression rating scale; MISS: Mississippi Scale for Combat-Related PTSD, civilian version; NIMH-OC: National Institute of Mental Health Obsessive-Compulsive Rating Scale; NIMH-GOCD: National Institute of Mental Health Global Obsessive-Compulsive Disorder Rating Scale; PANSS: Positive and Negative Syndrome Scale; PGIS: Patient rated global improvement scale; PRAS: Patient-Rated Anxiety Scale PSQ: Panic Self-Questionnaire; PSQI: Pittsburgh Sleep Quality Inventory; SADS: Schedule for Affective Disorders and Schizophrenia; SAS: Simpson-Angus Scale; SCID-P: Structured Interview for DSM-III-R with psychotic screen; SDS: Sheehan Disability Scale; SPI: Social Phobia Inventory; STSOBS: Schedule for Tourette's Syndrome and Other Behavioral Syndromes; UKUSERS: UKU Side Effect Rating Scale; YBOCS: Yale Brown Obsessive Compulsive Scale; YGTSS: Yale Global Tic Severity Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Denys-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an augmentation trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fallon-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study not an augmentation trial, as a washout period was initiated prior to randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grady-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not treatment resistant (check)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>The treatment resistant status of patients not determined through use of a valid scale, and not described as a treatment-resistant sample by the authors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mundo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not treatment resistant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otto-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation trial and comparison group receives medication and cognitive-behaviour therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pallanti-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not treatment resistant, as inclusion criteria specified that participants be SSRI naive.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pigott-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants not randomised, as design consisted of 2 weeks placebo followed by 10 weeks buspirone treatment. Possibility that sample contains participants from previous trial (Pigott 1991)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pollack-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were not treatment resistant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Fux-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Raskind-2006">
<CHAR_STUDY_NAME>
<P>Prazosin for Noncombat Trauma PTSD</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Persons with noncombat trauma PTSD (expected numbers not stated)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Double-blind placebo-controlled parallel group 8-week clinical trial of prazosin augmentation (following a 12-weeks of standard SSRI plus manualised psychotherapy treatment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Residual distressing trauma-related nightmares and sleep disturbance</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>May 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>PI Name: RASKIND, MURRAY A.<BR/>PI Email: murray.raskind@med.va.gov</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Grant Number: 1R01MH069867-01A2<BR/>Retrieved from CRISP</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Simon-2006">
<CHAR_STUDY_NAME>
<P>Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>80 GAD refractory despite an adequate treatment trial with a selective serotonin reuptake inhibitor (SSRI)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8 week addition of quetiapine to non-responders to 10 weeks of SSRI treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary Outcomes: Symptoms of generalized anxiety disorder<BR/>Secondary Outcomes: Clinical global improvement</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>February 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Alyson K Zalta, AB 617-726-4585 azalta@partners.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>ClinicalTrials.gov Identifier: NCT00113295<BR/>Retrieved from controlled-trials database</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Barr-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bartzokis-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brawman-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bystritsky-2004">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Carey-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dannon-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Denys-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Erzegovesi-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fineberg-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fux-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamner-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hirschmann-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koran-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-1991a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-1991b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McDougle-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pallanti-1999">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pigott-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pollack-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Raskind-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shapira-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stein-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stein-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Medication vs Placebo: Primary outcomes</NAME>
<DICH_OUTCOME CHI2="17.435968782819238" CI_END="9.231627452051255" CI_START="1.079560265681538" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1569127616723005" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" I2="59.85310545578895" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9652782699469444" LOG_CI_START="0.03324689152655388" LOG_EFFECT_SIZE="0.4992625807367492" METHOD="MH" NO="1" P_CHI2="0.014791278946335695" P_Q="0.0" P_Z="0.035747017472458884" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.217719455885049" TOTALS="YES" TOTAL_1="132" TOTAL_2="118" WEIGHT="100.0" Z="2.099793418395368">
<NAME>Clinical Global Impression (CGI-I) scale response - anxiety disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.435968782819238" CI_END="9.231627452051255" CI_START="1.079560265681538" DF="7.0" EFFECT_SIZE="3.1569127616723005" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" I2="59.85310545578895" ID="CMP-001.01.02" LOG_CI_END="0.9652782699469444" LOG_CI_START="0.03324689152655388" LOG_EFFECT_SIZE="0.4992625807367492" NO="2" P_CHI2="0.014791278946335695" P_Z="0.035747017472458884" STUDIES="9" TAU2="1.217719455885049" TOTAL_1="132" TOTAL_2="118" WEIGHT="100.0" Z="2.099793418395368">
<NAME>Obsessive compulsive disorder (OCD)</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="835" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="22.801365842091915"/>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="836" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="17.19922159660951"/>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="837" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="13.515423703819154"/>
<DICH_DATA CI_END="90.83421944759982" CI_START="0.3611155915913882" EFFECT_SIZE="5.7272727272727275" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9582494885828245" LOG_CI_START="-0.44235375999211124" LOG_EFFECT_SIZE="0.7579478642953567" ORDER="838" O_E="0.0" SE="1.410126231390647" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" VAR="1.9884559884559887" WEIGHT="9.348651882227273"/>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="839" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="9.203875605916732"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="840" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="841" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="9.68866159538441"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="842" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="9.25122149729552"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="843" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="8.991578276655494"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.435968782819238" CI_END="9.23162745205125" CI_START="1.0795602656815382" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1569127616723005" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" I2="59.85310545578895" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.9652782699469442" LOG_CI_START="0.03324689152655397" LOG_EFFECT_SIZE="0.4992625807367492" METHOD="MH" NO="2" P_CHI2="0.014791278946335695" P_Q="0.0" P_Z="0.03574701747245884" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.2177194558850488" TOTALS="YES" TOTAL_1="132" TOTAL_2="118" WEIGHT="100.0" Z="2.0997934183953686">
<NAME>Clinical Global Impressions (CGI-I) scale response - augmentation agents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.678864159052031" CI_END="12.717605819692125" CI_START="0.9911145879192175" DF="5.0" EFFECT_SIZE="3.550296417385906" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="15" I2="68.10993481875853" ID="CMP-001.02.01" LOG_CI_END="1.1044053599630872" LOG_CI_START="-0.003876131565069414" LOG_EFFECT_SIZE="0.5502646141990089" NO="1" P_CHI2="0.007823333470281968" P_Z="0.051624196621053435" STUDIES="6" TAU2="1.5074459382847305" TOTAL_1="97" TOTAL_2="90" WEIGHT="81.10746279869886" Z="1.946254329863065">
<NAME>antipsychotics</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="844" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="22.80136584209192"/>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="845" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="17.19922159660951"/>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="846" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="13.515423703819152"/>
<DICH_DATA CI_END="90.83421944759982" CI_START="0.3611155915913882" EFFECT_SIZE="5.7272727272727275" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9582494885828245" LOG_CI_START="-0.44235375999211124" LOG_EFFECT_SIZE="0.7579478642953567" ORDER="847" O_E="0.0" SE="1.410126231390647" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" VAR="1.9884559884559887" WEIGHT="9.348651882227271"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="848" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="9.251221497295516"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="849" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="8.991578276655494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.445432413949399" CI_END="23.37232679429486" CI_START="0.2211646901898075" DF="1.0" EFFECT_SIZE="2.273572830255314" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="30.816550787894016" ID="CMP-001.02.04" LOG_CI_END="1.368701950031126" LOG_CI_START="-0.6552842086503116" LOG_EFFECT_SIZE="0.3567088706904072" NO="4" P_CHI2="0.2292625552548665" P_Z="0.48965911908816284" STUDIES="3" TAU2="0.8718958075971517" TOTAL_1="35" TOTAL_2="28" WEIGHT="18.89253720130114" Z="0.6908511073757724">
<NAME>Other medications</NAME>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="850" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="9.20387560591673"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="851" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="852" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="9.688661595384406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.678864159052033" CI_END="12.717605819692121" CI_START="0.9911145879192172" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5502964173859053" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="15" I2="68.10993481875853" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.104405359963087" LOG_CI_START="-0.0038761315650695113" LOG_EFFECT_SIZE="0.5502646141990087" METHOD="MH" NO="3" P_CHI2="0.007823333470282079" P_Q="0.0" P_Z="0.051624196621053484" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.5074459382847307" TOTALS="YES" TOTAL_1="97" TOTAL_2="90" WEIGHT="100.0" Z="1.9462543298630646">
<NAME>Clinical Global Impressions (CGI-I) scale response - antipsychotics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="243.52369366651368" CI_START="0.9239347375706263" DF="0.0" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" NO="1" P_CHI2="1.0" P_Z="0.0568671838055408" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="12.007192896438632" Z="1.9043302740317438">
<NAME>haloperidol</NAME>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="853" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="12.007192896438632"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.807461232744938" CI_END="8.450454686145328" CI_START="0.2953498615076616" DF="1.0" EFFECT_SIZE="1.5798229714843979" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="79.19900022929514" ID="CMP-001.03.02" LOG_CI_END="0.9268800772776609" LOG_CI_START="-0.5296632284509354" LOG_EFFECT_SIZE="0.19860842441336268" NO="2" P_CHI2="0.02833686874314001" P_Z="0.5929917003699314" STUDIES="2" TAU2="1.1837880459744679" TOTAL_1="40" TOTAL_2="41" WEIGHT="47.270269491143225" Z="0.5345057127315788">
<NAME>quetiapine</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="854" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="26.417854346761967"/>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="855" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="20.85241514438126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04652223681959084" CI_END="22.84049767960972" CI_START="1.404416759423045" DF="2.0" EFFECT_SIZE="5.663707066472194" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="1.358705562671598" LOG_CI_START="0.147496003420428" LOG_EFFECT_SIZE="0.753100783046013" NO="3" P_CHI2="0.9770073478347342" P_Z="0.014796729489075972" STUDIES="3" TAU2="0.0" TOTAL_1="40" TOTAL_2="32" WEIGHT="40.72253761241815" Z="2.4373163177669546">
<NAME>risperidone</NAME>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="856" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="16.902221426403543"/>
<DICH_DATA CI_END="90.83421944759982" CI_START="0.3611155915913882" EFFECT_SIZE="5.7272727272727275" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9582494885828245" LOG_CI_START="-0.44235375999211124" LOG_EFFECT_SIZE="0.7579478642953567" ORDER="857" O_E="0.0" SE="1.410126231390647" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" VAR="1.9884559884559887" WEIGHT="12.123168026952492"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="858" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="11.697148159062117"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="56.442541767637536" CI_END="-0.4344970070714365" CI_START="-0.9026160484834176" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.668556527777427" ESTIMABLE="YES" I2="76.96772754579631" I2_Q="90.21496352011337" ID="CMP-001.04" NO="4" P_CHI2="2.2520565845507434E-7" P_Q="3.6446035318493664E-5" P_Z="2.164036658307499E-8" Q="20.43937193398355" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="160" UNITS="" WEIGHT="99.99999999999999" Z="5.598348283891758">
<NAME>Symptom severity scale - anxiety disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.538956689141361E-32" CI_END="-0.054372701660433176" CI_START="-1.9035320263877382" DF="0.0" EFFECT_SIZE="-0.9789523640240857" ESTIMABLE="YES" I2="100.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.0" P_Z="0.03796563193702845" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="12" WEIGHT="6.40861158241909" Z="2.0752255907970554">
<NAME>Generalized anxiety disorder (GAD)</NAME>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="859" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="6.40861158241909"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="36.003169833653985" CI_END="-0.30267561565382384" CI_START="-0.7942590544737477" DF="11.0" EFFECT_SIZE="-0.5484673350637858" ESTIMABLE="YES" I2="69.44713465280009" ID="CMP-001.04.02" NO="2" P_CHI2="1.6903079426877632E-4" P_Z="1.2225625114414661E-5" STUDIES="12" TAU2="0.0" TOTAL_1="155" TOTAL_2="136" WEIGHT="90.6813814184874" Z="4.373524974731568">
<NAME>Obsessive compulsive disorder</NAME>
<CONT_DATA CI_END="-1.0979786489803725" CI_START="-3.0193150620249134" EFFECT_SIZE="-2.058646855502643" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="21.4" ORDER="860" SD_1="3.2" SD_2="4.3" SE="0.49014584660733496" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" WEIGHT="5.936162580634204"/>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="861" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="14.566181545105811"/>
<CONT_DATA CI_END="-0.7344755310583464" CI_START="-3.5648057464042413" EFFECT_SIZE="-2.149640638731294" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="28.8" ORDER="862" SD_1="3.7" SD_2="2.4" SE="0.7220362817049646" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="2.7355105787441336"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="863" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.0778257396668"/>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="864" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.053006060441295"/>
<CONT_DATA CI_END="0.604277347529592" CI_START="-1.1170839278687943" EFFECT_SIZE="-0.2564032901696011" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="22.7" ORDER="865" SD_1="6.4" SD_2="5.5" SE="0.4391308434686209" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="7.39551729105673"/>
<CONT_DATA CI_END="0.4578031828220134" CI_START="-1.6187867928258841" EFFECT_SIZE="-0.5804918050019353" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="28.0" ORDER="866" SD_1="8.33" SD_2="7.31" SE="0.5297520750451983" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="5.081724395801511"/>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="867" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.775692596485161"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="868" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="3.27010701741658"/>
<CONT_DATA CI_END="1.1929209118204767" CI_START="-0.2106666793686594" EFFECT_SIZE="0.4911271162259086" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="21.0" ORDER="869" SD_1="6.6" SD_2="9.1" SE="0.3580646384985785" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="11.123298040033864"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="870" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="10.471245192445194"/>
<CONT_DATA CI_END="-0.8446615638626009" CI_START="-3.4635281461465275" EFFECT_SIZE="-2.154094855004564" ESTIMABLE="YES" MEAN_1="15.9" MEAN_2="25.6" ORDER="871" SD_1="3.8" SD_2="4.8" SE="0.6680904860857678" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="3.1951103806561347"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.355111376794918" CI_START="-5.099270496444298" DF="0.0" EFFECT_SIZE="-3.727190936619608" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="1.0" P_Z="1.0142512534401551E-7" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="2.9100069990934947" Z="5.3241519028327495">
<NAME>Panic DIsorder</NAME>
<CONT_DATA CI_END="-2.355111376794918" CI_START="-5.099270496444298" EFFECT_SIZE="-3.727190936619608" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="15.8" ORDER="872" SD_1="3.1" SD_2="1.3" SE="0.7000534553938125" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="2.9100069990934947"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="56.44254176763752" CI_END="-0.36252636681898254" CI_START="-1.3711866504984895" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.8668565086587361" ESTIMABLE="YES" I2="76.9677275457963" I2_Q="92.33297323648718" ID="CMP-001.05" NO="5" P_CHI2="2.2520565856609664E-7" P_Q="2.1654998304532214E-6" P_Z="7.548524350529284E-4" Q="26.085731297012657" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.6812594294839405" TOTALS="YES" TOTAL_1="177" TOTAL_2="160" UNITS="" WEIGHT="100.0" Z="3.3688399637138904">
<NAME>Symptom severity scale - augmentation agents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.548772257166236" CI_END="-0.3153998923729602" CI_START="-1.1110309471783766" DF="7.0" EFFECT_SIZE="-0.7132154197756684" ESTIMABLE="YES" I2="48.334802097676786" ID="CMP-001.05.01" NO="1" P_CHI2="0.059814157492597886" P_Z="4.416101303198227E-4" STUDIES="8" TAU2="0.1556630911817965" TOTAL_1="112" TOTAL_2="107" WEIGHT="61.4394367429202" Z="3.5138812833815245">
<NAME>antipsychotics</NAME>
<CONT_DATA CI_END="-1.0979786489803725" CI_START="-3.0193150620249134" EFFECT_SIZE="-2.058646855502643" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="21.4" ORDER="873" SD_1="3.2" SD_2="4.3" SE="0.49014584660733496" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" WEIGHT="7.185172624514882"/>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="874" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="8.497747354697921"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="875" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.37793840744112"/>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="876" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.494571741297461"/>
<CONT_DATA CI_END="0.604277347529592" CI_START="-1.1170839278687943" EFFECT_SIZE="-0.2564032901696011" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="22.7" ORDER="877" SD_1="6.4" SD_2="5.5" SE="0.4391308434686209" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="7.5748645159046"/>
<CONT_DATA CI_END="0.4578031828220134" CI_START="-1.6187867928258841" EFFECT_SIZE="-0.5804918050019353" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="28.0" ORDER="878" SD_1="8.33" SD_2="7.31" SE="0.5297520750451983" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="6.883435344663903"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="879" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="8.099731546775121"/>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="880" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="7.325975207625194"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4605866163839756" CI_END="-1.4024751387876573" CI_START="-4.4941729531785075" DF="1.0" EFFECT_SIZE="-2.948324045983082" ESTIMABLE="YES" I2="59.35928475992533" ID="CMP-001.05.02" NO="2" P_CHI2="0.11673542030051587" P_Z="1.853822699979771E-4" STUDIES="2" TAU2="0.7386268549301804" TOTAL_1="21" TOTAL_2="18" WEIGHT="11.158377584506372" Z="3.7381460231868116">
<NAME>beta-blockers</NAME>
<CONT_DATA CI_END="-0.7344755310583464" CI_START="-3.5648057464042413" EFFECT_SIZE="-2.149640638731294" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="28.8" ORDER="881" SD_1="3.7" SD_2="2.4" SE="0.7220362817049646" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="5.505718179348064"/>
<CONT_DATA CI_END="-2.355111376794918" CI_START="-5.099270496444298" EFFECT_SIZE="-3.727190936619608" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="15.8" ORDER="882" SD_1="3.1" SD_2="1.3" SE="0.7000534553938125" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="5.652659405158309"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.347451597074652" CI_END="0.7742011350355089" CI_START="-1.4329684750151765" DF="3.0" EFFECT_SIZE="-0.3293836699898338" ESTIMABLE="YES" I2="79.09036333245635" ID="CMP-001.05.04" NO="4" P_CHI2="0.0024684146043039146" P_Z="0.5585580658302822" STUDIES="4" TAU2="0.9781866214650284" TOTAL_1="44" TOTAL_2="35" WEIGHT="27.402185672573427" Z="0.5849846131769418">
<NAME>Other medications</NAME>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="883" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.42501964800762"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="884" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="5.925670458736368"/>
<CONT_DATA CI_END="1.1929209118204767" CI_START="-0.2106666793686594" EFFECT_SIZE="0.4911271162259086" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="21.0" ORDER="885" SD_1="6.6" SD_2="9.1" SE="0.3580646384985785" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="8.179618775123824"/>
<CONT_DATA CI_END="-0.8446615638626009" CI_START="-3.4635281461465275" EFFECT_SIZE="-2.154094855004564" ESTIMABLE="YES" MEAN_1="15.9" MEAN_2="25.6" ORDER="886" SD_1="3.8" SD_2="4.8" SE="0.6680904860857678" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="5.871876790705614"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.548772257166233" CI_END="-0.3153998923729601" CI_START="-1.1110309471783764" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7132154197756683" ESTIMABLE="YES" I2="48.33480209767677" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.05981415749259733" P_Q="0.7951790138423673" P_Z="4.416101303198227E-4" Q="0.45837644621012785" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15566309118179644" TOTALS="YES" TOTAL_1="112" TOTAL_2="107" UNITS="" WEIGHT="100.0" Z="3.5138812833815245">
<NAME>Symptom severity scale - antipsychotics</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.538956689141361E-32" CI_END="-0.054372701660433065" CI_START="-1.9035320263877384" DF="0.0" EFFECT_SIZE="-0.9789523640240857" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.0" P_Z="0.037965631937028475" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="12" WEIGHT="10.893097222736039" Z="2.075225590797055">
<NAME>olanzapine</NAME>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="887" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="10.893097222736039"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.886113752009713" CI_END="-0.018581345159787266" CI_START="-1.517443576047269" DF="3.0" EFFECT_SIZE="-0.7680124606035281" ESTIMABLE="YES" I2="74.76046365875678" ID="CMP-001.06.02" NO="2" P_CHI2="0.007783655134842582" P_Z="0.04458390176754802" STUDIES="4" TAU2="0.4306191308036086" TOTAL_1="65" TOTAL_2="64" WEIGHT="54.03702118740614" Z="2.008559201027599">
<NAME>quetiapine</NAME>
<CONT_DATA CI_END="-1.0979786489803725" CI_START="-3.0193150620249134" EFFECT_SIZE="-2.058646855502643" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="21.4" ORDER="888" SD_1="3.2" SD_2="4.3" SE="0.49014584660733496" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" WEIGHT="10.405792198476062"/>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="889" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="16.24689667023011"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="890" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.563018237135974"/>
<CONT_DATA CI_END="0.604277347529592" CI_START="-1.1170839278687943" EFFECT_SIZE="-0.2564032901696011" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="22.7" ORDER="891" SD_1="6.4" SD_2="5.5" SE="0.4391308434686209" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="11.821314081563994"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2042820589463914" CI_END="-0.138567061836758" CI_START="-1.1231327106806666" DF="2.0" EFFECT_SIZE="-0.6308498862587123" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" NO="3" P_CHI2="0.5476381226158311" P_Z="0.012016758128800386" STUDIES="3" TAU2="0.0" TOTAL_1="38" TOTAL_2="31" WEIGHT="35.06988158985782" Z="2.5116518297588692">
<NAME>risperidone</NAME>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="892" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.511973635817514"/>
<CONT_DATA CI_END="0.4578031828220134" CI_START="-1.6187867928258841" EFFECT_SIZE="-0.5804918050019353" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="28.0" ORDER="893" SD_1="8.33" SD_2="7.31" SE="0.5297520750451983" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="9.442385237067167"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="894" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="14.115522716973143"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Medication vs Placebo: Comorbid symptoms</NAME>
<CONT_OUTCOME CHI2="44.320136401131286" CI_END="0.22924277002603602" CI_START="-0.6976860484980132" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23422163923598857" ESTIMABLE="YES" I2="72.92427105505547" I2_Q="85.92703730903416" ID="CMP-002.01" NO="1" P_CHI2="1.3467924971810596E-5" P_Q="8.203157345341161E-4" P_Z="0.3219250799333877" Q="14.21164856270033" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5132016772846856" TOTALS="YES" TOTAL_1="163" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.9905096661757545">
<NAME>Depression scale (typically Hamilton Depression Scale) - Anxiety disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.635257614024912E-32" CI_END="0.006373888007752848" CI_START="-1.8269172084622198" DF="0.0" EFFECT_SIZE="-0.9102716602272335" ESTIMABLE="YES" I2="100.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.0" P_Z="0.051614465175737846" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="12" WEIGHT="7.6395284239618215" Z="1.9463353895387017">
<NAME>Generalized anxiety disorder (GAD)</NAME>
<CONT_DATA CI_END="0.006373888007752959" CI_START="-1.8269172084622198" EFFECT_SIZE="-0.9102716602272334" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="13.2" ORDER="895" SD_1="3.4" SD_2="7.2" SE="0.46768489393956697" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="7.6395284239618215"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="30.108487838430957" CI_END="0.4115648312941511" CI_START="-0.4887382915821964" DF="10.0" EFFECT_SIZE="-0.03858673014402265" ESTIMABLE="YES" I2="66.7867743685359" ID="CMP-002.01.02" NO="2" P_CHI2="8.223280193150329E-4" P_Z="0.8665777932252445" STUDIES="11" TAU2="0.3724048919400132" TOTAL_1="141" TOTAL_2="123" WEIGHT="84.96540226088298" Z="0.16800697329989756">
<NAME>Obsessive compulsive disorder</NAME>
<CONT_DATA CI_END="0.7092459527959322" CI_START="-0.5325661570390366" EFFECT_SIZE="0.08833989787844775" ESTIMABLE="YES" MEAN_1="8.21" MEAN_2="7.71" ORDER="896" SD_1="4.79" SD_2="6.15" SE="0.3167946247048987" STUDY_ID="STD-Carey-2005" TOTAL_1="19" TOTAL_2="21" WEIGHT="9.11337403713481"/>
<CONT_DATA CI_END="1.1011505022058026" CI_START="-1.0161781240070662" EFFECT_SIZE="0.042486189099368264" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.5" ORDER="897" SD_1="7.6" SD_2="4.9" SE="0.5401447789127981" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="6.946456862149202"/>
<CONT_DATA CI_END="0.08042890945201564" CI_START="-1.1851079028421243" EFFECT_SIZE="-0.5523394966950543" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="8.7" ORDER="898" SD_1="4.8" SD_2="5.8" SE="0.322846955933" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.056232811256697"/>
<CONT_DATA CI_END="3.2867954997599864" CI_START="0.9925923823830547" EFFECT_SIZE="2.1396939410715206" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="4.5" ORDER="899" SD_1="3.78" SD_2="3.37" SE="0.5852666517021009" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.534244897636347"/>
<CONT_DATA CI_END="0.7138043504074484" CI_START="-1.0016566552912394" EFFECT_SIZE="-0.14392615244189552" ESTIMABLE="YES" MEAN_1="14.7" MEAN_2="16.1" ORDER="900" SD_1="9.0" SD_2="9.7" SE="0.4376256449684855" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="7.934531782797823"/>
<CONT_DATA CI_END="0.2732755554432168" CI_START="-1.8460432943855993" EFFECT_SIZE="-0.7863838694711912" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="16.3" ORDER="901" SD_1="7.24" SD_2="7.5" SE="0.5406524983483708" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="6.941724672275504"/>
<CONT_DATA CI_END="0.8545750927884569" CI_START="-0.9073961987547122" EFFECT_SIZE="-0.026410552983127635" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="21.7" ORDER="902" SD_1="8.2" SD_2="13.5" SE="0.44949073183011873" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.817765126191591"/>
<CONT_DATA CI_END="1.2754122550780729" CI_START="-1.2040929919075343" EFFECT_SIZE="0.03565963158526926" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="19.6" ORDER="903" SD_1="10.9" SD_2="9.3" SE="0.6325384717636722" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.122376059943003"/>
<CONT_DATA CI_END="1.34923786724187" CI_START="-0.07007093044537005" EFFECT_SIZE="0.63958346839825" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="11.7" ORDER="904" SD_1="10.7" SD_2="7.4" SE="0.3620752240557905" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="8.678573919258412"/>
<CONT_DATA CI_END="-0.3562087395959168" CI_START="-1.8173702006367074" EFFECT_SIZE="-1.086789470116312" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="15.2" ORDER="905" SD_1="4.9" SD_2="8.7" SE="0.3727521200813499" STUDY_ID="STD-McDougle-2000" TOTAL_1="19" TOTAL_2="15" WEIGHT="8.574165871830923"/>
<CONT_DATA CI_END="0.6664138886281116" CI_START="-1.326532390609842" EFFECT_SIZE="-0.3300592509908652" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="6.4" ORDER="906" SD_1="2.6" SD_2="1.8" SE="0.5084140052975614" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="7.245956220408674"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8999928691510961" CI_START="-2.8320228416161077" DF="0.0" EFFECT_SIZE="-1.866007855383602" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="1.0" P_Z="1.531073204034624E-4" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="7.39506931515519" Z="3.7859745899846993">
<NAME>Panic Disorder</NAME>
<CONT_DATA CI_END="-0.8999928691510961" CI_START="-2.8320228416161077" EFFECT_SIZE="-1.866007855383602" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="8.5" ORDER="907" SD_1="1.9" SD_2="3.0" SE="0.4928738455667087" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="7.39506931515519"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="44.32013640113128" CI_END="0.22924277002603602" CI_START="-0.6976860484980132" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.23422163923598857" ESTIMABLE="YES" I2="72.92427105505547" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.3467924971699574E-5" P_Q="0.49928974338267085" P_Z="0.3219250799333877" Q="0.4564458444605606" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.5132016772846855" TOTALS="YES" TOTAL_1="163" TOTAL_2="147" UNITS="" WEIGHT="100.00000000000001" Z="0.9905096661757545">
<NAME>Depression scale (typically Hamilton Depression Scale) - Augmentation agents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="26.572196746031498" CI_END="0.41799544130900984" CI_START="-0.8792157963113767" DF="6.0" EFFECT_SIZE="-0.23061017750118346" ESTIMABLE="YES" I2="77.420007621703" ID="CMP-002.02.01" NO="1" P_CHI2="1.7411769633224328E-4" P_Z="0.4858900982044988" STUDIES="7" TAU2="0.5774505683760657" TOTAL_1="98" TOTAL_2="94" WEIGHT="55.79380249689393" Z="0.6968605100890708">
<NAME>antipsychotics</NAME>
<CONT_DATA CI_END="0.7092459527959322" CI_START="-0.5325661570390366" EFFECT_SIZE="0.08833989787844775" ESTIMABLE="YES" MEAN_1="8.21" MEAN_2="7.71" ORDER="908" SD_1="4.79" SD_2="6.15" SE="0.3167946247048987" STUDY_ID="STD-Carey-2005" TOTAL_1="19" TOTAL_2="21" WEIGHT="9.11337403713481"/>
<CONT_DATA CI_END="0.08042890945201564" CI_START="-1.1851079028421243" EFFECT_SIZE="-0.5523394966950543" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="8.7" ORDER="909" SD_1="4.8" SD_2="5.8" SE="0.322846955933" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.056232811256699"/>
<CONT_DATA CI_END="3.2867954997599864" CI_START="0.9925923823830547" EFFECT_SIZE="2.1396939410715206" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="4.5" ORDER="910" SD_1="3.78" SD_2="3.37" SE="0.5852666517021009" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.534244897636347"/>
<CONT_DATA CI_END="0.7138043504074484" CI_START="-1.0016566552912394" EFFECT_SIZE="-0.14392615244189552" ESTIMABLE="YES" MEAN_1="14.7" MEAN_2="16.1" ORDER="911" SD_1="9.0" SD_2="9.7" SE="0.4376256449684855" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="7.934531782797825"/>
<CONT_DATA CI_END="0.2732755554432168" CI_START="-1.8460432943855993" EFFECT_SIZE="-0.7863838694711912" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="16.3" ORDER="912" SD_1="7.24" SD_2="7.5" SE="0.5406524983483708" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="6.941724672275504"/>
<CONT_DATA CI_END="-0.3562087395959168" CI_START="-1.8173702006367074" EFFECT_SIZE="-1.086789470116312" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="15.2" ORDER="913" SD_1="4.9" SD_2="8.7" SE="0.3727521200813499" STUDY_ID="STD-McDougle-2000" TOTAL_1="19" TOTAL_2="15" WEIGHT="8.574165871830925"/>
<CONT_DATA CI_END="0.006373888007752959" CI_START="-1.8269172084622198" EFFECT_SIZE="-0.9102716602272334" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="13.2" ORDER="914" SD_1="3.4" SD_2="7.2" SE="0.46768489393956697" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="7.6395284239618215"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.29149381063922" CI_END="0.4885043335981698" CI_START="-0.9592805036893837" DF="5.0" EFFECT_SIZE="-0.23538808504560696" ESTIMABLE="YES" I2="71.0840482912843" ID="CMP-002.02.04" NO="4" P_CHI2="0.003978902472737023" P_Z="0.5239154827186943" STUDIES="6" TAU2="0.5721219567100603" TOTAL_1="65" TOTAL_2="53" WEIGHT="44.20619750310608" Z="0.6373214544000767">
<NAME>Other medications</NAME>
<CONT_DATA CI_END="1.1011505022058026" CI_START="-1.0161781240070662" EFFECT_SIZE="0.042486189099368264" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.5" ORDER="915" SD_1="7.6" SD_2="4.9" SE="0.5401447789127981" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="6.946456862149204"/>
<CONT_DATA CI_END="-0.8999928691510961" CI_START="-2.8320228416161077" EFFECT_SIZE="-1.866007855383602" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="8.5" ORDER="916" SD_1="1.9" SD_2="3.0" SE="0.4928738455667087" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="7.395069315155192"/>
<CONT_DATA CI_END="0.8545750927884569" CI_START="-0.9073961987547122" EFFECT_SIZE="-0.026410552983127635" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="21.7" ORDER="917" SD_1="8.2" SD_2="13.5" SE="0.44949073183011873" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.817765126191593"/>
<CONT_DATA CI_END="1.2754122550780729" CI_START="-1.2040929919075343" EFFECT_SIZE="0.03565963158526926" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="19.6" ORDER="918" SD_1="10.9" SD_2="9.3" SE="0.6325384717636722" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.1223760599430035"/>
<CONT_DATA CI_END="1.34923786724187" CI_START="-0.07007093044537005" EFFECT_SIZE="0.63958346839825" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="11.7" ORDER="919" SD_1="10.7" SD_2="7.4" SE="0.3620752240557905" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="8.678573919258413"/>
<CONT_DATA CI_END="0.6664138886281116" CI_START="-1.326532390609842" EFFECT_SIZE="-0.3300592509908652" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="6.4" ORDER="920" SD_1="2.6" SD_2="1.8" SE="0.5084140052975614" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="7.245956220408675"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="30.199577640257544" CI_END="2.0253552016579173" CI_START="-4.693880367101337" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3342625827217096" ESTIMABLE="YES" I2="80.1321724711749" I2_Q="93.52592837610246" ID="CMP-002.03" NO="3" P_CHI2="3.6018796334746916E-5" P_Q="8.488657382310638E-5" P_Z="0.43633673198948375" Q="15.446230102069485" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="15.965168779446218" TOTALS="YES" TOTAL_1="94" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="0.778394084057047">
<NAME>Hamilton Anxiety Rating Scale (HAM-A) - Anxiety disorders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.1446952356735665" CI_START="-8.855304764326434" DF="0.0" EFFECT_SIZE="-6.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="6.338928435462293E-8" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="16.877299866738575" Z="5.408967065522686">
<NAME>Panic Disorder</NAME>
<CONT_DATA CI_END="-4.1446952356735665" CI_START="-8.855304764326434" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="9.9" ORDER="921" SD_1="2.5" SD_2="3.4" SE="1.2017081859180971" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="16.877299866738575"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="14.75334753818806" CI_END="2.76526452921586" CI_START="-3.428975008077828" DF="5.0" EFFECT_SIZE="-0.3318552394309838" ESTIMABLE="YES" I2="66.10938644902228" ID="CMP-002.03.02" NO="2" P_CHI2="0.011469921521061188" P_Z="0.8336603232689924" STUDIES="6" TAU2="9.783799163738804" TOTAL_1="81" TOTAL_2="69" WEIGHT="83.12270013326143" Z="0.21000941712041707">
<NAME>Obsessive compulsive disorder</NAME>
<CONT_DATA CI_END="3.4740235163885815" CI_START="-6.37402351638858" EFFECT_SIZE="-1.4499999999999993" ESTIMABLE="YES" MEAN_1="10.25" MEAN_2="11.7" ORDER="922" SD_1="3.8" SD_2="5.2" SE="2.512303060274908" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="13.18955260217451"/>
<CONT_DATA CI_END="2.021678484158376" CI_START="-5.621678484158378" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="11.3" ORDER="923" SD_1="5.2" SD_2="7.0" SE="1.9498717906570167" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.864116161744182"/>
<CONT_DATA CI_END="6.035373428419807" CI_START="-2.8353734284198078" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="12.0" ORDER="924" SD_1="4.4" SD_2="5.5" SE="2.2629872096658237" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="13.934249874870916"/>
<CONT_DATA CI_END="9.750415422257339" CI_START="-1.7504154222573387" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="8.4" ORDER="925" SD_1="5.2" SD_2="4.0" SE="2.93393933134276" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="11.957004632314785"/>
<CONT_DATA CI_END="6.992117176987765" CI_START="-0.9921171769877652" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="8.6" ORDER="926" SD_1="6.8" SD_2="4.9" SE="2.036831905319218" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="14.607916895533238"/>
<CONT_DATA CI_END="-2.282684707014928" CI_START="-10.317315292985073" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="15.4" ORDER="927" SD_1="4.3" SD_2="6.9" SE="2.0496883231901926" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="14.569859966623804"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="30.199577640257544" CI_END="2.0253552016579173" CI_START="-4.693880367101337" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3342625827217096" ESTIMABLE="YES" I2="80.1321724711749" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="3.6018796334746916E-5" P_Q="0.32023788481109206" P_Z="0.43633673198948375" Q="0.9879756300288207" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="15.965168779446218" TOTALS="YES" TOTAL_1="94" TOTAL_2="81" UNITS="" WEIGHT="100.0" Z="0.778394084057047">
<NAME>Hamilton Anxiety Rating Scale (HAM-A) - Augmentation agents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.530230879229199" CI_END="0.40341990829164764" CI_START="-8.414703858908933" DF="1.0" EFFECT_SIZE="-4.0056419753086425" ESTIMABLE="YES" I2="60.47791495198903" ID="CMP-002.04.01" NO="1" P_CHI2="0.11168418825774162" P_Z="0.07497268766947433" STUDIES="2" TAU2="6.123388888888887" TOTAL_1="38" TOTAL_2="35" WEIGHT="29.43397612836798" Z="1.7806313936687208">
<NAME>antipsychotics</NAME>
<CONT_DATA CI_END="2.021678484158376" CI_START="-5.621678484158378" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="11.3" ORDER="928" SD_1="5.2" SD_2="7.0" SE="1.9498717906570167" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.864116161744178"/>
<CONT_DATA CI_END="-2.282684707014928" CI_START="-10.317315292985073" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="9.1" MEAN_2="15.4" ORDER="929" SD_1="4.3" SD_2="6.9" SE="2.0496883231901926" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="14.5698599666238"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="26.681371130999523" CI_END="4.557309266481807" CI_START="-4.78760575364956" DF="4.0" EFFECT_SIZE="-0.11514824358387665" ESTIMABLE="YES" I2="85.00826670278337" ID="CMP-002.04.04" NO="4" P_CHI2="2.3056082472328043E-5" P_Z="0.9614760096282726" STUDIES="5" TAU2="23.48864393781858" TOTAL_1="56" TOTAL_2="46" WEIGHT="70.56602387163201" Z="0.04830143662542819">
<NAME>Other medications</NAME>
<CONT_DATA CI_END="3.4740235163885815" CI_START="-6.37402351638858" EFFECT_SIZE="-1.4499999999999993" ESTIMABLE="YES" MEAN_1="10.25" MEAN_2="11.7" ORDER="930" SD_1="3.8" SD_2="5.2" SE="2.512303060274908" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="13.189552602174507"/>
<CONT_DATA CI_END="-4.1446952356735665" CI_START="-8.855304764326434" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="9.9" ORDER="931" SD_1="2.5" SD_2="3.4" SE="1.2017081859180971" STUDY_ID="STD-Hirschmann-2000" TOTAL_1="13" TOTAL_2="12" WEIGHT="16.87729986673857"/>
<CONT_DATA CI_END="6.035373428419807" CI_START="-2.8353734284198078" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="12.0" ORDER="932" SD_1="4.4" SD_2="5.5" SE="2.2629872096658237" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="13.934249874870913"/>
<CONT_DATA CI_END="9.750415422257339" CI_START="-1.7504154222573387" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="8.4" ORDER="933" SD_1="5.2" SD_2="4.0" SE="2.93393933134276" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="11.957004632314783"/>
<CONT_DATA CI_END="6.992117176987765" CI_START="-0.9921171769877652" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="8.6" ORDER="934" SD_1="6.8" SD_2="4.9" SE="2.036831905319218" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="14.607916895533235"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Medication vs Placebo: Quality of Life Scales</NAME>
<CONT_OUTCOME CHI2="2.022448967644528" CI_END="0.19240527703745935" CI_START="-2.5490233091216163" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1783090160420784" ESTIMABLE="YES" I2="1.109989325004989" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.3637733955885193" P_Q="1.0" P_Z="0.09201818306481731" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.029757741764078156" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" UNITS="" WEIGHT="100.00000000000001" Z="1.6848465400566839">
<NAME>Sheehan Disability Scale</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="3.9996931941955576" CI_START="-2.399693194195558" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-6.1" ORDER="935" SD_1="5.6" SD_2="4.8" SE="1.6325265257088035" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="18.149093992698006"/>
<CONT_DATA CI_END="-0.18118598181777945" CI_START="-3.218814018182221" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="5.8" ORDER="936" SD_1="2.5" SD_2="2.4" SE="0.7749193506423749" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="77.60317887352251"/>
<CONT_DATA CI_END="6.542119967416683" CI_START="-6.742119967416686" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="18.5" MEAN_2="18.6" ORDER="937" SD_1="8.6" SD_2="6.9" SE="3.3888989898839363" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="4.247727133779494"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Medication vs Placebo: Drop-out Rate</NAME>
<DICH_OUTCOME CHI2="3.349341387233078" CI_END="7.278613718037433" CI_START="0.6423793268937346" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1623207396018724" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.862048671629437" LOG_CI_START="-0.19220844400652706" LOG_EFFECT_SIZE="0.3349201138114549" METHOD="MH" NO="1" P_CHI2="0.5011529221004629" P_Q="0.0" P_Z="0.21302279694778536" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="117" WEIGHT="100.00000000000001" Z="1.2452965240315703">
<NAME>Drop-out rate due to treatment emergent adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1611808915582728" CI_END="13.697348619311342" CI_START="0.9444182610266223" DF="3.0" EFFECT_SIZE="3.5966687592445075" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.1366365093870143" LOG_CI_START="-0.024835624106628238" LOG_EFFECT_SIZE="0.555900442640193" NO="1" P_CHI2="0.9835984082072065" P_Z="0.060635424294191886" STUDIES="7" TAU2="0.0" TOTAL_1="107" TOTAL_2="102" WEIGHT="82.39018781889227" Z="1.8761446187905744">
<NAME>antipsychotics</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="938" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.80796493228969" CI_START="0.26688245158268314" EFFECT_SIZE="5.238095238095238" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0120267624427464" LOG_CI_START="-0.5736799815941351" LOG_EFFECT_SIZE="0.7191733904243057" ORDER="939" O_E="0.0" SE="1.5188569409020742" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="2.306926406926407" WEIGHT="16.623962309206103"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="940" O_E="0.0" SE="0.0" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="941" O_E="0.0" SE="0.0" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="60.69595725305233" CI_START="0.12459643676877162" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7831597651912086" LOG_CI_START="-0.9044943775306834" LOG_EFFECT_SIZE="0.43933269383026263" ORDER="942" O_E="0.0" SE="1.5787413475374117" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" VAR="2.492424242424242" WEIGHT="15.386729508599105"/>
<DICH_DATA CI_END="55.88985168824527" CI_START="0.10552826685911433" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7473329571546035" LOG_CI_START="-0.9766311944265694" LOG_EFFECT_SIZE="0.3853508813640171" ORDER="943" O_E="0.0" SE="1.600070026478796" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.5602240896358546" WEIGHT="14.979258180603825"/>
<DICH_DATA CI_END="30.762288933068753" CI_START="0.520117343504968" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.488018646929696" LOG_CI_START="-0.28389866427377153" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="944" O_E="0.0" SE="1.0408329997330665" STUDY_ID="STD-Pollack-2006" TOTAL_1="12" TOTAL_2="12" VAR="1.0833333333333335" WEIGHT="35.40023782048324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6072254556040475" CI_START="0.011088854991821353" DF="0.0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.5571732870549357" LOG_CI_START="-1.9551132957269735" LOG_EFFECT_SIZE="-0.6989700043360187" NO="3" P_CHI2="1.0" P_Z="0.27544678733539196" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="17.609812181107742" Z="1.0906049048396544">
<NAME>beta-blockers</NAME>
<DICH_DATA CI_END="3.6072254556040475" CI_START="0.011088854991821353" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5571732870549357" LOG_CI_START="-1.9551132957269735" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="945" O_E="0.0" SE="1.4757295747452437" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="8" VAR="2.1777777777777776" WEIGHT="17.609812181107742"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="946" O_E="0.0" SE="0.0" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Subgroup analyses - Methodological criteria</NAME>
<DICH_OUTCOME CHI2="17.43596878281924" CI_END="9.23162745205125" CI_START="1.0795602656815377" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1569127616722996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" I2="59.85310545578895" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.9652782699469442" LOG_CI_START="0.033246891526553794" LOG_EFFECT_SIZE="0.499262580736749" METHOD="MH" NO="5" P_CHI2="0.014791278946335695" P_Q="0.0" P_Z="0.03574701747245892" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.2177194558850495" TOTALS="YES" TOTAL_1="132" TOTAL_2="118" WEIGHT="100.0" Z="2.0997934183953677">
<NAME>Industry versus non-industry funded trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.72694732982972" CI_END="8.965093853180283" CI_START="0.608359319840897" DF="4.0" EFFECT_SIZE="2.3353797119163646" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="15" I2="65.89052643030774" ID="CMP-005.05.01" LOG_CI_END="0.952554840435285" LOG_CI_START="-0.21583983432860193" LOG_EFFECT_SIZE="0.36835750305334153" NO="1" P_CHI2="0.019501592454773786" P_Z="0.21652252040705156" STUDIES="5" TAU2="1.357356396483254" TOTAL_1="86" TOTAL_2="78" WEIGHT="68.28912241360862" Z="1.2358280211531263">
<NAME>Industry funded trials</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="947" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="22.801365842091908"/>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="948" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="17.199221596609508"/>
<DICH_DATA CI_END="90.83421944759982" CI_START="0.3611155915913882" EFFECT_SIZE="5.7272727272727275" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9582494885828245" LOG_CI_START="-0.44235375999211124" LOG_EFFECT_SIZE="0.7579478642953567" ORDER="949" O_E="0.0" SE="1.410126231390647" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" VAR="1.9884559884559887" WEIGHT="9.348651882227273"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="950" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="9.688661595384408"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="951" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="9.251221497295518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07724827800346079" CI_END="24.538629032638514" CI_START="1.4955787121347133" DF="2.0" EFFECT_SIZE="6.058007197600957" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="1.3898502951394702" LOG_CI_START="0.1748092748372083" LOG_EFFECT_SIZE="0.7823297849883393" NO="2" P_CHI2="0.9621122623641334" P_Z="0.011605159889425298" STUDIES="4" TAU2="0.0" TOTAL_1="46" TOTAL_2="40" WEIGHT="31.710877586391373" Z="2.523928290468194">
<NAME>Non-industry funded trials</NAME>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="952" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="13.51542370381915"/>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="953" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="9.20387560591673"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="954" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="955" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="8.991578276655492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="14.617091370815752" CI_END="-0.031010575386273054" CI_START="-0.6923664858430898" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3616885306146814" ESTIMABLE="YES" I2="38.42824285843041" I2_Q="0.0" ID="CMP-005.07" NO="7" P_CHI2="0.10200530932012664" P_Q="0.7335790544837888" P_Z="0.03205155937097288" Q="0.1158507450101478" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1063637269841667" TOTALS="YES" TOTAL_1="133" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="2.1437670168739675">
<NAME>Industry versus non-industry funded trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.814670760520341" CI_END="0.16675018330472552" CI_START="-0.8979504778071026" DF="4.0" EFFECT_SIZE="-0.36560014725118856" ESTIMABLE="YES" I2="59.24468484373353" ID="CMP-005.07.01" NO="1" P_CHI2="0.04366802454163632" P_Z="0.17829065737045277" STUDIES="5" TAU2="0.21350235393346753" TOTAL_1="78" TOTAL_2="73" WEIGHT="55.294321709906306" Z="1.3460367735783865">
<NAME>Industry funded trials</NAME>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="956" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="13.935084881297929"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="957" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.214275213378919"/>
<CONT_DATA CI_END="0.4578031828220134" CI_START="-1.6187867928258841" EFFECT_SIZE="-0.5804918050019353" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="28.0" ORDER="958" SD_1="8.33" SD_2="7.31" SE="0.5297520750451983" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="7.355331165880245"/>
<CONT_DATA CI_END="1.1929209118204767" CI_START="-0.2106666793686594" EFFECT_SIZE="0.4911271162259086" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="21.0" ORDER="959" SD_1="6.6" SD_2="9.1" SE="0.3580646384985785" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="12.134849892420798"/>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="960" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="8.65478055692842"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.6865698652852625" CI_END="0.03411650899402113" CI_START="-0.8305134885559879" DF="4.0" EFFECT_SIZE="-0.3981984897809834" ESTIMABLE="YES" I2="14.649730720347907" ID="CMP-005.07.02" NO="2" P_CHI2="0.320994758230434" P_Z="0.07102904068478103" STUDIES="5" TAU2="0.035965791285522554" TOTAL_1="55" TOTAL_2="49" WEIGHT="44.705678290093694" Z="1.8052917453256132">
<NAME>Non-industry funded trials</NAME>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="961" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.22505059738049"/>
<CONT_DATA CI_END="0.604277347529592" CI_START="-1.1170839278687943" EFFECT_SIZE="-0.2564032901696011" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="22.7" ORDER="962" SD_1="6.4" SD_2="5.5" SE="0.4391308434686209" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="9.513783419339308"/>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="963" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="8.984099747769877"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="964" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="5.2473116386006"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="965" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="11.735432887003421"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Subgroup analyses - Clinical criteria</NAME>
<DICH_OUTCOME CHI2="14.131183835867619" CI_END="20.976081122662947" CI_START="0.7532242705199977" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9748828161325833" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="71.69380820135363" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.3217243539349082" LOG_CI_START="-0.12307569451957037" LOG_EFFECT_SIZE="0.5993243297076689" METHOD="MH" NO="1" P_CHI2="0.0068879378619748355" P_Q="0.0" P_Z="0.10394033197845878" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.349375825385731" TOTALS="YES" TOTAL_1="81" TOTAL_2="77" WEIGHT="100.0" Z="1.626043828752889">
<NAME>Inclusion of major depression vs. non-inclusion: CGI-I</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15691856243393365" CI_END="48.205532174946484" CI_START="1.8791616404746347" DF="2.0" EFFECT_SIZE="9.517667094505104" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.6830968817073853" LOG_CI_START="0.27396413856082885" LOG_EFFECT_SIZE="0.9785305101341071" NO="1" P_CHI2="0.9245397285065906" P_Z="0.006487284592663204" STUDIES="4" TAU2="0.0" TOTAL_1="51" TOTAL_2="46" WEIGHT="49.05150933624021" Z="2.722077912055142">
<NAME>Trials including patients with major depressive disorder</NAME>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="966" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="16.41337459678809"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="967" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="968" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="16.47595039637"/>
<DICH_DATA CI_END="130.37605312207955" CI_START="0.44057510438294345" EFFECT_SIZE="7.578947368421052" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.115197829494113" LOG_CI_START="-0.3559800472092721" LOG_EFFECT_SIZE="0.8796088911424207" ORDER="969" O_E="0.0" SE="1.451582117303342" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" VAR="2.1070906432748537" WEIGHT="16.16218434308212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5158018749738167" CI_END="10.378244653381595" CI_START="0.24608766235863005" DF="1.0" EFFECT_SIZE="1.5981107490210518" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" I2="71.5569865549535" ID="CMP-006.01.02" LOG_CI_END="1.0161239043971841" LOG_CI_START="-0.6089101591695288" LOG_EFFECT_SIZE="0.20360687261382765" NO="2" P_CHI2="0.060786368657134715" P_Z="0.6233252383565424" STUDIES="2" TAU2="1.3796976949261177" TOTAL_1="30" TOTAL_2="31" WEIGHT="50.948490663759785" Z="0.49114310435075276">
<NAME>Trials excluding patients with major depressive disorder</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="970" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="29.44411601599637"/>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="971" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="21.504374647763417"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.419126834432348" CI_END="-0.3882065305929137" CI_START="-1.3470537255880963" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.867630128090505" ESTIMABLE="YES" I2="64.59359104417095" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.0025409013087447363" P_Q="0.43462973880537903" P_Z="3.8961897902041627E-4" Q="0.610420427939335" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.36554520597055823" TOTALS="YES" TOTAL_1="124" TOTAL_2="118" UNITS="" WEIGHT="99.99999999999997" Z="3.5470173179529563">
<NAME>Inclusion of major depression vs. non-inclusion</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.88749361005281" CI_END="-0.1052141229161433" CI_START="-1.5483969540831444" DF="4.0" EFFECT_SIZE="-0.8268055384996439" ESTIMABLE="YES" I2="66.35119116600534" ID="CMP-006.02.01" NO="1" P_CHI2="0.018207819325585795" P_Z="0.024720455788318895" STUDIES="5" TAU2="0.44145363970913787" TOTAL_1="57" TOTAL_2="54" WEIGHT="49.827547269876476" Z="2.2457432872412357">
<NAME>Trials including patients with major depressive disorder</NAME>
<CONT_DATA CI_END="-1.0979786489803725" CI_START="-3.0193150620249134" EFFECT_SIZE="-2.058646855502643" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="21.4" ORDER="972" SD_1="3.2" SD_2="4.3" SE="0.49014584660733496" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" WEIGHT="9.876927187371582"/>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="973" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="10.387334052749726"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="974" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="7.463729094126292"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="975" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="11.925169361925615"/>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="976" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="10.174387573703262"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.921212796440203" CI_END="-0.20408295743311822" CI_START="-1.6340671236945354" DF="4.0" EFFECT_SIZE="-0.9190750405638268" ESTIMABLE="YES" I2="69.04315358770346" ID="CMP-006.02.02" NO="2" P_CHI2="0.011667271887200625" P_Z="0.011755366111958548" STUDIES="5" TAU2="0.43075799558559524" TOTAL_1="67" TOTAL_2="64" WEIGHT="50.1724527301235" Z="2.5194040900526757">
<NAME>Trials excluding patients with major depressive disorder</NAME>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="977" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="12.910358895402005"/>
<CONT_DATA CI_END="-0.7344755310583464" CI_START="-3.5648057464042413" EFFECT_SIZE="-2.149640638731294" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="28.8" ORDER="978" SD_1="3.7" SD_2="2.4" SE="0.7220362817049646" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="6.746476113462305"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="979" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.607250470626216"/>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="980" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.538742358618949"/>
<CONT_DATA CI_END="-0.8446615638626009" CI_START="-3.4635281461465275" EFFECT_SIZE="-2.154094855004564" ESTIMABLE="YES" MEAN_1="15.9" MEAN_2="25.6" ORDER="981" SD_1="3.8" SD_2="4.8" SE="0.6680904860857678" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="7.369624892014031"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="17.435968782819238" CI_END="9.23162745205125" CI_START="1.079560265681538" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1569127616722996" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="16" I2="59.85310545578895" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.9652782699469442" LOG_CI_START="0.03324689152655388" LOG_EFFECT_SIZE="0.499262580736749" METHOD="MH" NO="3" P_CHI2="0.014791278946335695" P_Q="0.0" P_Z="0.035747017472458884" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.2177194558850493" TOTALS="YES" TOTAL_1="132" TOTAL_2="118" WEIGHT="100.0" Z="2.099793418395368">
<NAME>Adequate previous trials versus inadequate trials: CGI-I</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.200776949552308" CI_END="12.378177993524597" CI_START="0.5602424815135004" DF="3.0" EFFECT_SIZE="2.6333972650756707" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" I2="63.41810027934275" ID="CMP-006.03.01" LOG_CI_END="1.0926567233923228" LOG_CI_START="-0.25162396301085527" LOG_EFFECT_SIZE="0.4205163801907338" NO="1" P_CHI2="0.042039509801385044" P_Z="0.22011310551165597" STUDIES="5" TAU2="1.4800657033924034" TOTAL_1="65" TOTAL_2="58" WEIGHT="54.65701970479384" Z="1.2262274812386866">
<NAME>Validated treatment-resistant sample</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="982" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="22.801365842091915"/>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="983" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="13.515423703819154"/>
<DICH_DATA CI_END="90.83421944759982" CI_START="0.3611155915913882" EFFECT_SIZE="5.7272727272727275" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9582494885828245" LOG_CI_START="-0.44235375999211124" LOG_EFFECT_SIZE="0.7579478642953567" ORDER="984" O_E="0.0" SE="1.410126231390647" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" VAR="1.9884559884559887" WEIGHT="9.348651882227273"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="985" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="126.06834462038681" CI_START="0.42105441150115064" EFFECT_SIZE="7.285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.100606050232446" LOG_CI_START="-0.37566177806508694" LOG_EFFECT_SIZE="0.8624721360836796" ORDER="986" O_E="0.0" SE="1.4545719800654109" STUDY_ID="STD-McDougle-2000" TOTAL_1="20" TOTAL_2="16" VAR="2.1157796451914104" WEIGHT="8.991578276655492"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6921369324386415" CI_END="11.743051516001866" CI_START="1.4112468077545157" DF="3.0" EFFECT_SIZE="4.070914389330051" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="1.0697809661072883" LOG_CI_START="0.14960297255841545" LOG_EFFECT_SIZE="0.6096919693328519" NO="2" P_CHI2="0.44156525955110315" P_Z="0.009396865060972983" STUDIES="4" TAU2="0.0" TOTAL_1="67" TOTAL_2="60" WEIGHT="45.34298029520617" Z="2.597267724143244">
<NAME>Non-validated sample</NAME>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="987" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="17.199221596609508"/>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="988" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="9.20387560591673"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="989" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="9.68866159538441"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="990" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="9.25122149729552"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="36.78096864010993" CI_END="-0.24650702625826615" CI_START="-1.1072912076949635" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6768991169766148" ESTIMABLE="YES" I2="67.37443182256514" I2_Q="26.089596013904178" ID="CMP-006.04" NO="4" P_CHI2="2.4242449243561115E-4" P_Q="0.24475633430278887" P_Z="0.0020524686336724665" Q="1.3529894927757695" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4022998962980582" TOTALS="YES" TOTAL_1="164" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="3.082533157676752">
<NAME>Adequate previous trials versus inadequate trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="26.132970603610808" CI_END="-0.23956628001298264" CI_START="-1.3833205019369874" DF="8.0" EFFECT_SIZE="-0.811443390974985" ESTIMABLE="YES" I2="69.38733019928996" ID="CMP-006.04.01" NO="1" P_CHI2="9.966584817505675E-4" P_Z="0.005418894195832894" STUDIES="9" TAU2="0.506390655598511" TOTAL_1="105" TOTAL_2="93" WEIGHT="65.89388245022731" Z="2.7810167452386407">
<NAME>Validated treatment-resistant sample</NAME>
<CONT_DATA CI_END="-1.0979786489803725" CI_START="-3.0193150620249134" EFFECT_SIZE="-2.058646855502643" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="21.4" ORDER="991" SD_1="3.2" SD_2="4.3" SE="0.49014584660733496" STUDY_ID="STD-Atmaca-2002" TOTAL_1="14" TOTAL_2="13" WEIGHT="7.504647330088221"/>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="992" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="9.640139039508178"/>
<CONT_DATA CI_END="-0.7344755310583464" CI_START="-3.5648057464042413" EFFECT_SIZE="-2.149640638731294" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="28.8" ORDER="993" SD_1="3.7" SD_2="2.4" SE="0.7220362817049646" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="5.220731930544422"/>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="994" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.976930448143128"/>
<CONT_DATA CI_END="0.604277347529592" CI_START="-1.1170839278687943" EFFECT_SIZE="-0.2564032901696011" ESTIMABLE="YES" MEAN_1="21.1" MEAN_2="22.7" ORDER="995" SD_1="6.4" SD_2="5.5" SE="0.4391308434686209" STUDY_ID="STD-Fineberg-2005" TOTAL_1="11" TOTAL_2="10" WEIGHT="8.102449074293267"/>
<CONT_DATA CI_END="0.4578031828220134" CI_START="-1.6187867928258841" EFFECT_SIZE="-0.5804918050019353" ESTIMABLE="YES" MEAN_1="23.1" MEAN_2="28.0" ORDER="996" SD_1="8.33" SD_2="7.31" SE="0.5297520750451983" STUDY_ID="STD-Hollander-2003" TOTAL_1="10" TOTAL_2="6" WEIGHT="7.060763075206786"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="997" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="5.75144276342255"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="998" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="8.9547107462757"/>
<CONT_DATA CI_END="-0.8446615638626009" CI_START="-3.4635281461465275" EFFECT_SIZE="-2.154094855004564" ESTIMABLE="YES" MEAN_1="15.9" MEAN_2="25.6" ORDER="999" SD_1="3.8" SD_2="4.8" SE="0.6680904860857678" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="5.682068042745061"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.295008543723357" CI_END="0.2565094907227435" CI_START="-1.1196154525823594" DF="3.0" EFFECT_SIZE="-0.43155298092980793" ESTIMABLE="YES" I2="67.72461277589885" ID="CMP-006.04.02" NO="2" P_CHI2="0.025615209558545016" P_Z="0.2189631270635648" STUDIES="4" TAU2="0.3303620965292267" TOTAL_1="59" TOTAL_2="55" WEIGHT="34.10611754977269" Z="1.22928997713225">
<NAME>Non-validated sample</NAME>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="1000" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.43007675425687"/>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="1001" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="7.869201227028336"/>
<CONT_DATA CI_END="1.1929209118204767" CI_START="-0.2106666793686594" EFFECT_SIZE="0.4911271162259086" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="21.0" ORDER="1002" SD_1="6.6" SD_2="9.1" SE="0.3580646384985785" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="9.089472040146605"/>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="1003" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="7.717367528340876"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.323949089171784" CI_END="9.560770825715014" CI_START="0.9518287473461542" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.016656513211933" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="16" I2="63.24418823396111" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.9804929081609483" LOG_CI_START="-0.02144118267944702" LOG_EFFECT_SIZE="0.4795258627407506" METHOD="MH" NO="5" P_CHI2="0.01211689323155063" P_Q="0.0" P_Z="0.0606445240893715" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.3151237997305554" TOTALS="YES" TOTAL_1="120" TOTAL_2="111" WEIGHT="100.0" Z="1.8760783353305108">
<NAME>Non-responders versus partial responders: CGI-I</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.807461232744938" CI_END="8.450454686145328" CI_START="0.2953498615076616" DF="1.0" EFFECT_SIZE="1.5798229714843979" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="79.19900022929514" ID="CMP-006.05.01" LOG_CI_END="0.9268800772776609" LOG_CI_START="-0.5296632284509354" LOG_EFFECT_SIZE="0.19860842441336268" NO="1" P_CHI2="0.02833686874314001" P_Z="0.5929917003699314" STUDIES="2" TAU2="1.1837880459744679" TOTAL_1="40" TOTAL_2="41" WEIGHT="43.35584786715464" Z="0.5345057127315788">
<NAME>Non-responder trials</NAME>
<DICH_DATA CI_END="1.4491624424328944" CI_START="0.4279411554158582" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.16111707001091874" LOG_CI_START="-0.3686159450876426" LOG_EFFECT_SIZE="-0.1037494375383619" ORDER="1004" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" VAR="0.09682539682539681" WEIGHT="24.53208387663751"/>
<DICH_DATA CI_END="16.55061376388459" CI_START="0.9667315199460398" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.2188141038111788" LOG_CI_START="-0.014694121155254024" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1005" O_E="0.0" SE="0.7245688373094719" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.5249999999999999" WEIGHT="18.823763990517122"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7975580997020733" CI_END="15.108945466476316" CI_START="1.56725825079173" DF="4.0" EFFECT_SIZE="4.866170922100591" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="1.1792341536790447" LOG_CI_START="0.1951405648494158" LOG_EFFECT_SIZE="0.6871873592642304" NO="2" P_CHI2="0.5922543349484326" P_Z="0.006195236298735295" STUDIES="6" TAU2="0.0" TOTAL_1="80" TOTAL_2="70" WEIGHT="56.644152132845356" Z="2.7372650123468163">
<NAME>Partial responder trials</NAME>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1006" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="14.961643141283806"/>
<DICH_DATA CI_END="123.16550987916884" CI_START="0.45670253023905705" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.090489109076517" LOG_CI_START="-0.34036658229311684" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="1007" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" VAR="2.0388888888888888" WEIGHT="10.327347966509647"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1008" O_E="0.0" SE="0.0" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="1009" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="10.854705491840322"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="1010" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-McDougle-1994" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="10.378922620434135"/>
<DICH_DATA CI_END="130.37605312207955" CI_START="0.44057510438294345" EFFECT_SIZE="7.578947368421052" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.115197829494113" LOG_CI_START="-0.3559800472092721" LOG_EFFECT_SIZE="0.8796088911424207" ORDER="1011" O_E="0.0" SE="1.451582117303342" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" VAR="2.1070906432748537" WEIGHT="10.121532912777441"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="26.73900127306025" CI_END="-0.11663402832612946" CI_START="-1.0670058313426485" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.591819929834389" ESTIMABLE="YES" I2="66.34130082836127" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.0015447491196250995" P_Q="0.34011037077355455" P_Z="0.014645207085784885" Q="0.9100157465512702" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.36801792778128456" TOTALS="YES" TOTAL_1="129" TOTAL_2="119" UNITS="" WEIGHT="100.0" Z="2.4410356959806867">
<NAME>Non-responders versus partial responders</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.303066989371652" CI_END="-0.16527795043277627" CI_START="-1.2393403280356758" DF="4.0" EFFECT_SIZE="-0.702309139234226" ESTIMABLE="YES" I2="51.82503037588155" ID="CMP-006.06.01" NO="1" P_CHI2="0.08108656916496171" P_Z="0.010372214633020767" STUDIES="5" TAU2="0.186762587124622" TOTAL_1="67" TOTAL_2="69" WEIGHT="51.80812535104524" Z="2.5631669959141363">
<NAME>Non-responder trials</NAME>
<CONT_DATA CI_END="0.4673527821262623" CI_START="-0.7591921088288013" EFFECT_SIZE="-0.1459196633512695" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.52" ORDER="1012" SD_1="7.66" SD_2="8.68" SE="0.3128998544437278" STUDY_ID="STD-Carey-2005" TOTAL_1="20" TOTAL_2="21" WEIGHT="12.615823372602424"/>
<CONT_DATA CI_END="-0.7344755310583464" CI_START="-3.5648057464042413" EFFECT_SIZE="-2.149640638731294" ESTIMABLE="YES" MEAN_1="21.4" MEAN_2="28.8" ORDER="1013" SD_1="3.7" SD_2="2.4" SE="0.7220362817049646" STUDY_ID="STD-Dannon-2000" TOTAL_1="8" TOTAL_2="6" WEIGHT="6.609309551762423"/>
<CONT_DATA CI_END="-0.16060647231091985" CI_START="-1.4550661715134643" EFFECT_SIZE="-0.8078363219121921" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="24.6" ORDER="1014" SD_1="6.4" SD_2="6.7" SE="0.33022537898988896" STUDY_ID="STD-Denys-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.321165253280434"/>
<CONT_DATA CI_END="0.6154752268343915" CI_START="-1.1471873274416502" EFFECT_SIZE="-0.2658560503036293" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="24.6" ORDER="1015" SD_1="4.57" SD_2="6.75" SE="0.4496670776044098" STUDY_ID="STD-Erzegovesi-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.308362399470495"/>
<CONT_DATA CI_END="-0.054372701660433065" CI_START="-1.903532026387738" EFFECT_SIZE="-0.9789523640240856" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="18.7" ORDER="1016" SD_1="6.4" SD_2="9.2" SE="0.47173298573678846" STUDY_ID="STD-Pollack-2006" TOTAL_1="9" TOTAL_2="12" WEIGHT="9.953464773929465"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.52591853713733" CI_END="0.4219894086167907" CI_START="-1.3205386344173053" DF="4.0" EFFECT_SIZE="-0.4492746129002573" ESTIMABLE="YES" I2="77.17665986222622" ID="CMP-006.06.02" NO="2" P_CHI2="0.0015271365074560617" P_Z="0.31217350625943563" STUDIES="5" TAU2="0.7357340990882233" TOTAL_1="62" TOTAL_2="50" WEIGHT="48.19187464895476" Z="1.010671895896081">
<NAME>Partial responder trials</NAME>
<CONT_DATA CI_END="0.37803060042224546" CI_START="-1.420341100100782" EFFECT_SIZE="-0.5211552498392683" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.8" ORDER="1017" SD_1="6.5" SD_2="5.0" SE="0.45877672107966116" STUDY_ID="STD-McDougle-1991a" TOTAL_1="11" TOTAL_2="9" WEIGHT="10.160896956929669"/>
<CONT_DATA CI_END="1.9558701110669823" CI_START="-0.632791743865365" EFFECT_SIZE="0.6615391836008087" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="22.6" ORDER="1018" SD_1="6.3" SD_2="5.7" SE="0.6603850569070099" STUDY_ID="STD-McDougle-1991b" TOTAL_1="5" TOTAL_2="5" WEIGHT="7.309818901903079"/>
<CONT_DATA CI_END="1.1929209118204767" CI_START="-0.2106666793686594" EFFECT_SIZE="0.4911271162259086" ESTIMABLE="YES" MEAN_1="24.9" MEAN_2="21.0" ORDER="1019" SD_1="6.6" SD_2="9.1" SE="0.3580646384985785" STUDY_ID="STD-McDougle-1993" TOTAL_1="19" TOTAL_2="14" WEIGHT="11.845392595216914"/>
<CONT_DATA CI_END="-0.17781938799967545" CI_START="-1.6244483064885151" EFFECT_SIZE="-0.9011338472440953" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="25.0" ORDER="1020" SD_1="8.3" SD_2="4.4" SE="0.3690447706946821" STUDY_ID="STD-McDougle-2000" TOTAL_1="18" TOTAL_2="15" WEIGHT="11.657831119661981"/>
<CONT_DATA CI_END="-0.8446615638626009" CI_START="-3.4635281461465275" EFFECT_SIZE="-2.154094855004564" ESTIMABLE="YES" MEAN_1="15.9" MEAN_2="25.6" ORDER="1021" SD_1="3.8" SD_2="4.8" SE="0.6680904860857678" STUDY_ID="STD-Pallanti-1999" TOTAL_1="9" TOTAL_2="7" WEIGHT="7.217935075243116"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Sensitivity analyses</NAME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Pub Bias - Response.</P>
<P>Evidence of small sample effect on the CGI-I</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA
JFUAJKoAJP8ASQAASVUASaoASf8AawAAa1UAa6oAa/8AkgAAklUAkqoAkv8AtgAAtlUAtqoAtv8A
2wAA21UA26oA2/8A/wAA/1UA/6oA//8kAAAkAFUkAKokAP8kJAAkJFUkJKokJP8kSQAkSVUkSaok
Sf8kawAka1Uka6oka/8kkgAkklUkkqokkv8ktgAktlUktqoktv8k2wAk21Uk26ok2/8k/wAk/1Uk
/6ok//9JAABJAFVJAKpJAP9JJABJJFVJJKpJJP9JSQBJSVVJSapJSf9JawBJa1VJa6pJa/9JkgBJ
klVJkqpJkv9JtgBJtlVJtqpJtv9J2wBJ21VJ26pJ2/9J/wBJ/1VJ/6pJ//9rAABrAFVrAKprAP9r
JABrJFVrJKprJP9rSQBrSVVrSaprSf9rawBra1Vra6pra/9rkgBrklVrkqprkv9rtgBrtlVrtqpr
tv9r2wBr21Vr26pr2/9r/wBr/1Vr/6pr//+SAACSAFWSAKqSAP+SJACSJFWSJKqSJP+SSQCSSVWS
SaqSSf+SawCSa1WSa6qSa/+SkgCSklWSkqqSkv+StgCStlWStqqStv+S2wCS21WS26qS2/+S/wCS
/1WS/6qS//+2AAC2AFW2AKq2AP+2JAC2JFW2JKq2JP+2SQC2SVW2Saq2Sf+2awC2a1W2a6q2a/+2
kgC2klW2kqq2kv+2tgC2tlW2tqq2tv+22wC221W226q22/+2/wC2/1W2/6q2///bAADbAFXbAKrb
AP/bJADbJFXbJKrbJP/bSQDbSVXbSarbSf/bawDba1Xba6rba//bkgDbklXbkqrbkv/btgDbtlXb
tqrbtv/b2wDb21Xb26rb2//b/wDb/1Xb/6rb////AAD/AFX/AKr/AP//JAD/JFX/JKr/JP//SQD/
SVX/Sar/Sf//awD/a1X/a6r/a///kgD/klX/kqr/kv//tgD/tlX/tqr/tv//2wD/21X/26r/2///
/wD//1X//6r////30rcGAAAXFklEQVR42u2dAWwU15nH33Z3c5iCgCYV4soli1ikcBcIoaKImF63
Vyc2BKU4dtLLcQ4QG4Uc7oWosTC641IIUUzcXKhkJAi44ZLLFelMTBQajGQ3S3tcxaGcIkxEUhvF
JzW6cs0VU5A2l13H9968mdmZ8a69i2cN6/39JO/Mzr753pvn/775z7zP48CwAPCfL9EFgLAAYQHC
AkBYgLAAYQEgLEBYgLAAEBYgLChJgj/MsDF13+O7dr3c7Nr04L0z8wxtRPna4tx3bPzTafnXMkq0
mWOFtYuMeDPyeJ0b3EWzbcq+2Y7l+ThLkGzFWy9k7tzWC0tvvLBCGbeWXYyI+kMNznLH848toyS+
GstdiAN+HpgdTa5kabyrQk/tI3ZxbMjQ0Cxtz7LZiuX5OFsHZCl+nb+VGyosxZozoneJmD7Yu7ND
9O48srbtqnqXWtsW6dw4KFpnNdTXjS2acEwMt+6fPqhDpb4b2X+yrby56dbmphZji0hVxkVPTK5X
d7x84q73PYV7bjXWasubqzs63+gQiTmDMmiv1RDZiMQ00Vi2u9YZM1Vz2+HpgzLaeaPFKuxW1fjq
Dv2J8aVuNit8yqrELi90SPN4dUn1W1279wfm3q79dGvUpmcyNyIi97UPRYeTbf9XswG6Tldpx/6d
decjrWesvpefP3fa6oTO2ikbZlmBhNGBRjWX1XZHD541239TnAq/OLJ6pvjR3Ys3nXz5gS1P/vO9
M19btOTI/U3q3V9+8t9L22bcO21P48zvRkYPraL835bNx+57q2/GXBmqb8bth+976/b2ZUfWPHzk
0WeMLZFNq956qPKZv25/9eTvnnzvuCqgCz+wpVaum7u1L3vr5O++d/COyN4/q5C/Jr1RRv/3sqWb
n3yr48t/4Ygpd/zJ91/tm/G9947rveXK7Ufub1Q1LDE+Ub+7Nz541q7QLqbrfUSHNI93oVFyqTqa
qjfNvZen93tgy0N2JZkboTrpC7u0DrfkyJ/8zGyAeYSO0inHllULXwr/4D+/MNvy0nvH77M6IbHi
oxf2LrICLTY6cImsZraxfbHdg1et9t8cI1ZivhDVDb0n5GJ6qL57w+ljKXHBeCeqdq67VN+9fEpk
7NgqyoFIWYW4sz92TI5MK1bKdVFWEV5VEV75G73lUoVYNJh4L6YGSHX2VIVv1TXJ9ZAuNL1Bfhyq
6lp5qk01WW/UVRxtV3uaMU+YO0ZkkJWugkldg/GJHGcXXg6q0VJXaBfTR2iGNN8dMUqap3Zzb7Oh
ukC6ksyNcJc+YlZsN8Dc3VHauSVW3V93XlhtUR9andBfFRFVwjoSswNlNXr7BbsHFzraf3N4rPoV
whxDq+bceqda6ncLP+uOVtVdrsrNYwnjtycFMK2np96tuj/ybkmjzz3e3RrnrDPknN744YpsO2ap
1D7qnlRlsGm3t5ixe8IVTBglW7I3c2Ql7kZ01orpn3rC7U43IEPHOLekuhLdDc6YVie4j+TZrD0Y
GqX9N+Z2w4Gfxhdejqt+KVvXrb8bxrvQt/ZXhZP/VZFnPdNjicMZtoRmd8ue/OTrcXE8an9i1pTe
7arxcVlNc6NjY2JAmtmyGvlRph09lYbdNfTODPW83+8tpne3Qup37pIuzNq8R+ZpRPXQ0KAYES4d
NkvHmLy87NrWAWdMqxOiXQOpLvtI0oent6fLj9L+G2TeQ41rzu81/Kao2LhPbTDfVe3cF1p5Rn5r
cjHv9uBVE5y2oT/DlgOVT4ieqAzd1CBm3/W+rtqoKZUuNOW571TL7+3Wb/4svWeo8TtTNgjRJp12
us32jnJ99l3ndUEVNmTUYA8ji/4uKMrOh3SFZVYx83jNkObxGiU9XaP3MwukK8nciIhzsxXObsB5
R8fo0s6uan1+ULy+5FNrZ/W51Qm/mq8O3wpkH57enm7DogztnxACRfDHFOoC0OjmWQ2ZPq5f0eB3
jQUI6RdZOqGIbjfcbCSmZXKh9YdFtc89XYCQBe6Em5EAf/4FE2reARAWICwoDTJO6chrjz/f1fvI
GNdqY2YiJKbsSqj7XfVqHkSk7rtQIXr/+FuRdCXe2fmx0xuyZ0xkbI4uvlTkk52RJcUA/Lgq7Dwz
5MluyLDnmDPrjQc2VMZj8iqrzng75UMhuqpGiZE9DyFNnhkTRvGKSB55AP7mWCAsN8cbhdguzDlz
M3Vgt5Fj4EhT2OuaWdeJA86bpqlLFaGq/lhrnXUBWjEQ+SRmzt7bs/NzrfSGzHkIOreio9UxRx9W
VXhyI+T6cOt+qzGuZoRjqQdUa/e6sw/kETR+4siXMHIOIq2zLp+46/zcdMpFypU4IVpvUK7AJPFY
qUvyOx6Nprb2DM04JK7OutY669p+uZTvUtsvDtXExWf3DMVE75khtUWXulantrc7BpPkv0VEtF80
2Zvu6E78RgaXEX5Zm6i7eOVDtfGJR4feX6ujPr3qfES4wqmpyQE5zOmarLhxHUR+bu/8y1rVJLsx
rmaYrbWOI30EL12Oi7bN6nj1XgaqETqs6+h1Ja52QP4jlvkrsebMjVn7AZ1jkE5T8MysO6b+sxA9
3V912Zx5t2bnU0Z6g8iah2DmVthz9DpjwkoBMHbutafyt+5cZ+dJCEdxo7WetAqV1mClCiTde6Wc
KReunIUjNypXYJIIKzR7IJLNkDvm3rPMrNvnoJUDkf6o0/B81rXsrDnz3ps1qgcjtyI9R29mTLhy
I9zpBF6P5f3Isas3VSBDvoRwVSJuVK7AZLndsEZ+j+trPSkBOsfAMffunVkfIc/uVJfrgztOx6yZ
emt2Xqc3DGTNQ9C5FSPn6B25EWV6Kj/RLfZWZW2Md1cd20wVMPcy8iXsNrlTLsbMdYBcToXV/UH1
FXWnBOgcA8fcu3dmXXgyHtqmPdHkOjlWnBb2NL85O6/TGxZmzUPQuRUj5ui9uRHSjU+/HJTN03kS
oyVeOLMHzFQBXacw8iVUioEj5cJqSPZcB8hI7nOFVo7BZKJYUgUmzamwNEgEn0dXN37EAmDEAoQF
CAsgV7JkN3Te5Xh2w/XO97uzG8yUidSD33hMJxq4Ew7Md7LiXV9ban3kLGKs55akMLKUbIpuS+Yy
vVsesRI6nA2Qr38/3lyHzh2PZGlcMT2JIX+yZDdsHBKdM83Ji+ue7/dkN+iUiQ12okGmhANVcaoy
unKcB+WNnFrTE0tVZk3XSO04ZiV0eBvQWje+OefUP5XLLsjUuKJ6EoNfwjp+TIjq4/GVOcz3Z78X
6c1uMFMm5G9ZPwXBndqgd2k7pv7wTP1NsE5TsFMW7Cm61FpnsoX3qQj2sxE8z2ooi4hQj3BlQ4h0
2LfXWK1zNEBTtlzpYsTDF+xMD7uSVivTwz2Z+PadVW/ERNE/icEnYRnZDfbffD99qi1S/2hP7zc/
3doTk0PO1VnXph24Nmf39ouR3tqO9qyhjeyGM6JJvJ4OGtUTd9eebq+Pr1SpDSqsDGS807PBUtKy
UErX9dk9Q/I1XUAYSQpG9VdnDekCqbWqIc8aI85yc1Q0dzfqiamp7PlSUJ76UvoAlOTrrNYl7AZY
KF0I4almg67cUcmtersd0v6K1i08PxDRB1z9+jPrnh9MmRUfOdU293g8ZqRXJOouzq28R6h8EWHH
lXUmvqq2m+Xl+94c8uRu6hErw+CTZb7/+mo1H1UwIrXBOBvWiqbd6cwKsXVng6uAK9lixFMRzGci
eHIkRLX8hXynZ6WrPvuBCPp7JNwNsOnXlbqrMSp3VrLS2N7r7ZPeK9IK7G8Rxf4kBp+EpbMbPjTO
YWPN92fHk92QNWXCkdoQ/no8Vj3UeSZrgVEaohMPnA9lcNO+dedKdzjnAZitSzeg8xnzmQuZqhlZ
gc6/WGeFVH96rxSwtzMoVbl5rvn9LNonMfh1u2HNWtk3R2M5zPePpllPdoNOmfCUcKc2hBrXmmOE
lXCgUhYyPN9AWMkWwp14YKUfeLIcEsG4EF1Rd332AUhRWa1LN8B65oL91XDlNxiVOyvR2+2Q5t6J
o0OSZ7vNEMX7JAa/ToXVIqi+caEc5vtHSSTwZDfolAlXcpQjtSFdsWhqSVlJDjplYcSDHxRGskVK
uBMPImb6gSdHouz9Jcb33lWf9TAKKSp5ujQTOuwG2GfCKvfx6gp0poejknSmh/NcpS4F1Li0QV9h
Fu+TGPKnaOcK/Uy2SNUey3ovLuPtBt8qn7zpFdx5V4PRc1lP6U0/KmC9kzm9guwGYMQChAUICwBh
AcIChAWAsABhAcICQFhw0zNaol9iqtjW4loZwbm7hfpo42G5PmNQ5dmOzHbY06w/NJfJh4/R7aUt
rC0H11cZfwlgr3hJbv84Iurj5f8jF+rto4PJ30a8hX79rtz1xUMN1rI8YygoGWElL1WEK1Vir72S
mXaROK3VtHmrSMnVjYe/1BOTrw/NVKOX+jdtInlyh7UU8/sRVkkLS2lk/lnnygjCL8yr6RDinSsB
IaZ+8IcrMdFXITbOHpanxMfLXz362A5Zpk99GHglds5cimEeMFWKwgqYy9zSaRYPHw1sa7l40Egr
erFKPRY50TkoQuUX3vyJWB1WA1mf9GDKeFnLSQ1ZSFmvCocl6kVqrnxAXFSp1/bKiJPlWiFqPv9Q
fKQ/VIuPon3qv+ueTsrXPvWXTcaebWvTy8yhoHRuN4RndydPRp0rI0p85ZAQF+IOwy5XF5wYEH+z
eUG3SG5V+yRPqX/XWxO3lnoDlPJV4b6pm7bF1OlLr2TgwP2bxIzBc+/Mk+s1HXdqO/baPHUHoj1Q
tiJqGjQhVnctN5ext6sjk7c7OROOagqu0ym8+ft0BvfRsy36j8e9JOo6Sq07ORWOk1Vd6fUHzwSm
ZboRmpjDP3Yo+VNhvpQ5NBN+N0sZnr/PiAV4LIR1k3gsugBhAcIChIXHAoSFx0JYgLAAEBYeC2Hh
sRAWICwAhIXHQlh4LIQFgLAAYeGxEBbgsRAWICxAWIDHQlh4LIQFCAsAYeGxEBYeC2EBICxAWHgs
hAV4LIQFCAsQFuCxEBYeC2EBwgIYByG6YAyCQgzhsRixCqAr4wePhbD81lU+ygKEBQiraMBjIazc
GHK84rEQlr/KGqIb8obbDbmNWcCIhcdCWJMOPBbCAoQFk8u8J6aqf+5scG4X/xgVj+XXiLXl4Odn
48Za8il6Co/ll7CSlyrClf3G6suL6CnwS1ip0xEx3xDWuf9ooKdgfB4rYL443EJy+74/0FN4rPEJ
S3VNwOifUPlA5GJUrlx4Z54Qtbj3XDwWyhr7qjA8u3v9yR1yZfEwV4Xg41Xhvk23LIuJ+ji9BP6M
3QzoUMgRC/L/ntIFCAsQFiCs0gZzirDwWAgLEBYAwsJjISw8FsICQFiAsPBYCAuPhbDoAkBYgLDw
WAgL8FgICxAWICzAYyEsPBbCAoQFgLDwWAgLj4WwABAWICw8FsICPBbCAoQFCAvwWAgLj4WwAGEB
ICw8FsLCYyEsAIQFCAuPhbDAH48VDAYRFvhO0PxBWOC3rkpQWQgLj4WwitRjISwoAEOOV4QF/iqr
5HQ12n9YBZ881lAp9gQjFh4LYcHkOBUmpoptLWrl3N1ixiB9BT4Ja8vB9VXxmBDJ7R9H9jS30FnX
6bE4FbpJXqoIV/Zb5iFKX+Gx/BmxUqcjYv5ZuRI+dv+pVxroKxiPsALmi2NQT9z2AadCGKewlKAC
hqpC5QORi+oM2LcqIv52DsLCY/njscKzu5MnlbAWnBgQ71TQV3gsn64K903dtC0m6utir83jdgP4
J6wyY2BvF6KGER78OxUCHgth4bEQFiAsAISFx0JYeCyEBYCwAGHhsRAW4LEQFiAsQFiAx0JYeCyE
BQgLAGHhsRAWHgthASAsQFh4LIQF4/BYpfTAd4Q1cZTUA98R1oTqqnSUhbDwWAir2D0WwoICUFoP
fEdYE6usknk0N895n0CPVUoPfGfEwmMhLEBYgLBgojwWwgI8FsIChAUIC/BYCAuPhbAAYQEgLDwW
wsJjISwAhAUIC4+FsACPhbAAYQHCAjxWvoz+xxT1dTG12NPMv+7N0WOhrFyEtfG1OrU498Kw1Bb/
xR58Elbren2iXCxHq1W76CvwyWM1xdLrP26kr/BY4xmxAuaLu4sevzdGX+GxxiOs4Qzdk6z8qwa6
Cvy7KjR1VfUPjFfgt7Dq6/735z8XoqaDzsJj+SWsdv1Dd+Gx/LwqBEBYgLDwWAgL8vRYdAHCAoQF
CAuPBQgLj4WwAGEBICw8FsLCYyEsQFgACAuPhbDwWAgLwG/4t3KjEyytfwbHiDVxusrr34PjsRBW
rrrKS1l4LIQFCAsQ1uQi7388j8dCWDkrK5+rwlw8VjAYLIGe43ZDLmOW7xeak/8WBiPWzXqhWeQD
G8LylTw91ijiyfcOGsKa1OR3H2sU8eR9Bw1hYdqs16IXD8Iq5gtNrgohN4+Vk6qGgqK4BciIdcM8
VnBUnRX7wMaIdaMIjjF+FfnpkhELENbk8FgICwrpsfKe4EZYkLOyJu99B8z7jVUWp0LAYyGsYvBY
CAsAYQHCwmMhLMBjISxAWICwAI+FsPBYCAsQFkDOjD4JXV8XU4tzd4sZg/QVHsuvEWvjYWOR3P7x
8PZm+gqP5dOI1bpey+5CWURso6vAL2E1ideNZd8d345zKoTxCStgvjjdwv4PIkebW+gsPNY4hKW6
JuDpn+9HxIKf0le5eCyUlcfthtX75ekwSl+Bb7cbzFsOvwiImg76CsY7djOgw0ScCiH37yldgLAA
YQHCKm0wpwgLj4WwAGEBICw8FsLCYyEsAIQFCAuPhbDwWAiLLgCEBQgLj4WwAI+FsABhAcICPBbC
wmMhLEBYAAgLj4Ww8FgICwBhAcLCYyEswGMhLEBYgLAAj4Ww8FgICxAWAMLCYyEsPBbCAkBYgLDw
WAgL8FgICxAWICzAYyEsPBbCAoQFgLDwWAgLj4WwAG5+YQWKN3qAfsk5OCMWHotTIR4LYUGpf8WG
+d5BARxAaMKtQmBYFGv0AP2CeQc8FpSKxwJgxAKEBaVD8IfWWuKWnZ9VpFest/UzIv7U5InvY2Rv
Bf6HtihUXB3ZcQCFCe13Bd7IzvjpEWvLwc/PxtMr5tuNh/1qhSe+j5G9Ffgf2qRQcc3I6QMoUGif
KxgR2RnfFlbyUkW4st9eMd+2rt/gUys88X2M7K3A/9AmhYprRk4fQIFC+1zBiMiu+LawUqcjYn6/
vWK+bYr51QxPfB8jeyvwP7RJoeKakdMHUKDQPlcwIrIrPuYdCntVGCofEBej9or91i888f0/kkLF
nTAKeAAF+p16Irvi28IKz+5OnozaK/Zbv/DE97/zChV3wijgARTod+qJ7IqfPhXu23TLspioj5sr
+tVHPPH9x66gWClUx9ihC1GBM7IzPlM6UFiPBYCwAGFBaRKiC8DDnmb5MmPQXioScwb3NNd84ysN
nrLn/uW5h48hLMiFX78rL+1ePNRgLeWm5KODyV98HBlZtisaLo/HOBXC2CSOSqEkT0atpdq2eWvy
/neWJGZKnYnElwfExkAwLpLfDtR8FM0yS8SIBR76rgSECLwSO2cu1QnvSkw0Lm85VyGefnjdbR9E
Xix/VZ4b/3H5u0cf2yGGERbkJKxtLaK+LmYv1QmvSqjJmr6oCNdN64kktolNYuqFFwbF6nAE8w65
oab72uYM2kvJR3XGj9pyfEpE9NV0qGGsQoqwQmSZfsRjgZvkKSmWspq4tbQ2/zaituyZ/av9YsGJ
AfH4oQXdIvlUVJdnxIKxUFlVQqzuWm4u1bnwTrm5LJI4HdkjT38/jsdemye2NYjtgakbqsTb1RnP
hswVwti8+fuGrNeQdR2CUyFcH6u6supqTmZdMWJBYWDEAoQFCAsQFgDCAoQFCAsAYQHCAoQF4Cf/
D6C0r0jJWP1MAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Pub Bias - Symptoms.</P>
<P>Evidence of small sample effect on measures of symptom severity</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Egger plot (CGI-I).</P>
<P>Regression of standardised treatment estimate for treatment response on measure of precision</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAf4AAAH9CAIAAAB0mYncAABMj0lEQVR42uzdeTyUe+P/8fvx+32/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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Egger plot (SMD).</P>
<P>Regression of standardised treatment estimate for continuous outcomes on measure of precision</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfYAAAH1CAIAAACLHUtFAAA4CklEQVR42u3de1xU9b7w8f16dc7r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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>